2-Chlorodeoxyadenosine and cytarabine combination therapy for idiopathic hypereosinophilic syndrome
artículo científico publicado en 2005
340B Drug Pricing Program Reform-Reply
artículo científico publicado en 2016
A Phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia
artículo científico publicado en 2004
A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
artículo científico publicado en 2015
A Phase II Study of Coltuximab Ravtansine (SAR3419) Monotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
artículo científico publicado en 2015
A cancer trial scandal and its regulatory backlash
artículo científico publicado en 2014
A critical appraisal of conventional and investigational drug therapy in patients with hypereosinophilic syndrome and clonal eosinophilia
artículo científico publicado en 2007
A fludarabine, topotecan, and cytarabine regimen is active in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2004
A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms
artículo científico publicado en 2009
A model for prediction of FLT3-ITD and NPM1 (without FLT3-ITD) positivity in patients with newly diagnosed acute myeloid leukaemia
artículo científico publicado en 2013
A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome
artículo científico publicado en 2007
A pathway-based gene signature correlates with therapeutic response in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
⬇️
artículo científico publicado el 20 de agosto de 2010
A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias
artículo científico publicado en 2011
A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia
artículo científico publicado en 2017
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome
artículo científico publicado en 2010
A phase 2 study of pracinostat combined with ruxolitinib in patients with myelofibrosis
artículo científico publicado en 2019
A phase 2 study of ruxolitinib in combination with azacitidine in patients with myelofibrosis
artículo científico publicado en 2018
A phase I and pharmacodynamic study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis
artículo científico publicado en 2013
A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generat
artículo científico publicado en 2015
A phase I study of fludarabine, cytarabine, and oxaliplatin therapy in patients with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2014
A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes
artículo científico publicado en 2002
A phase I study of intravenous LBH589, a novel cinnamic hydroxamic acid analogue histone deacetylase inhibitor, in patients with refractory hematologic malignancies
artículo científico publicado en 2006
A phase I study of moxetumomab pasudotox in adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.
artículo científico publicado en 2017
A phase I study of oral ARRY-614, a p38 MAPK/Tie2 dual inhibitor, in patients with low or intermediate-1 risk myelodysplastic syndromes
artículo científico publicado en 2014
A phase I study of pemetrexed in patients with relapsed or refractory acute leukemia
artículo científico publicado en 2010
A phase I study of the pan bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies
artículo científico publicado en 2008
A phase I study of vorinostat in combination with idarubicin in relapsed or refractory leukaemia
artículo científico publicado en 2010
A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML).
artículo científico publicado en 2016
A phase I, open-label, multi-center study of the JAK2 inhibitor AZD1480 in patients with myelofibrosis.
artículo científico publicado en 2014
A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2017
A phase I/II study of the Janus kinase (JAK)1 and 2 inhibitor ruxolitinib in patients with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2014
A phase II study of lenalidomide alone in relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes with chromosome 5 abnormalities
artículo científico publicado en 2012
A phase II study of omacetaxine mepesuccinate for patients with higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia after failure of hypomethylating agents
artículo científico publicado en 2018
A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome/myeloproliferative neoplasms.
artículo científico publicado en 2017
A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
artículo científico publicado en 2007
A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis
artículo científico publicado en 2015
A post hoc sensitivity analysis of survival probabilities in a multinational phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2013
A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry
artículo científico publicado en 2007
A potential role of ruxolitinib in leukemia
artículo científico publicado en 2011
A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia
artículo científico publicado en 2014
A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine)
artículo científico publicado en 2005
A propensity score matching analysis of dasatinib and nilotinib as a frontline therapy for patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2016
A prospective analysis of symptom burden for patients with chronic myeloid leukemia in chronic phase treated with frontline second- and third-generation tyrosine kinase inhibitors
artículo científico publicado en 2018
A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia
artículo científico publicado en 2012
A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2017
A randomized phase II study of low-dose decitabine versus low-dose azacitidine in lower risk MDS and MDS/MPN.
artículo científico publicado en 2017
A randomized study of 2 dose levels of intravenous clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
artículo científico publicado en 2011
A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome
artículo científico publicado en 2008
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome
artículo científico publicado en 2003
A retrospective comparison of three sequential groups of patients with Recurrent/Refractory chronic lymphocytic leukemia treated with fludarabine-based regimens
artículo científico publicado en 2006
A retrospective study of venous thromboembolism in acute leukemia patients treated at the University of Texas MD Anderson Cancer Center
artículo científico publicado en 2014
A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome
artículo científico publicado en 2003
AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia
artículo científico publicado en 2005
AMN107, a novel aminopyrimidine inhibitor of p190 Bcr-Abl activation and of in vitro proliferation of Philadelphia-positive acute lymphoblastic leukemia cells
artículo científico publicado en 2005
ATF4 induction through an atypical integrated stress response to ONC201 triggers p53-independent apoptosis in hematological malignancies
artículo científico publicado en 2016
Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
artículo científico publicado en 2008
Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia
artículo científico publicado en 2003
Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia
artículo científico publicado en 2011
Aberrant DNA methylation of a cell cycle regulatory pathway composed of P73, P15 and P57KIP2 is a rare event in children with acute lymphocytic leukemia.
artículo científico publicado en 2005
Aberrant DNA methylation of p57KIP2 identifies a cell-cycle regulatory pathway with prognostic impact in adult acute lymphocytic leukemia
artículo científico publicado en 2003
Accelerated and blastic phases of chronic myelogenous leukemia
artículo científico publicado en 2004
Acquisition of cytogenetic abnormalities in patients with IPSS defined lower-risk myelodysplastic syndrome is associated with poor prognosis and transformation to acute myelogenous leukemia
scientific article published on 23 July 2013
Activating internal tandem duplication mutations of the fms-like tyrosine kinase-3 (FLT3-ITD) at complete response and relapse in patients with acute myeloid leukemia
artículo científico publicado en 2012
Activation of p53 signaling by MI-63 induces apoptosis in acute myeloid leukemia cells
artículo científico publicado en 2010
Activity of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, against human FIP1L1-PDGFR-alpha-expressing cells
artículo científico publicado en 2006
Activity of decitabine in patients with myelodysplastic syndrome previously treated with azacitidine
artículo científico publicado en 2008
Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia
artículo científico publicado en 2007
Activity of the oral mitogen-activated protein kinase kinase inhibitor trametinib in RAS-mutant relapsed or refractory myeloid malignancies
artículo científico publicado en 2016
Acute Lymphoblastic Leukemia, Version 2.2015.
artículo científico publicado en 2015
Acute Myeloid Leukemia With t(v;5q33) Is Associated With Poor Overall Survival and Often Lacks Myelodysplastic Features
artículo científico publicado en 2015
Acute erythroid leukemia: a reassessment using criteria refined in the 2008 WHO classification
artículo científico publicado en 2010
Acute lymphoblastic leukemia arising in post-polycythemic myelofibrosis: a rare entity
artículo científico publicado en 2012
Acute lymphoblastic leukemia in adolescents and young adults
artículo científico publicado en 2017
Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates
artículo científico publicado en 2013
Acute myeloid leukemia after myelodysplastic syndrome and failure of therapy with hypomethylating agents: an emerging entity with a poor prognosis
artículo científico publicado en 2013
Acute myeloid leukemia with t(10;11): a pathological entity with distinct clinical presentation
artículo científico
Acute myeloid leukemia with t(9;11)(p21-22;q23): common properties of dysregulated ras pathway signaling and genomic progression characterize de novo and therapy-related cases
artículo científico publicado en 2010
Acute myeloid leukemia--major progress over four decades and glimpses into the future
artículo científico publicado en 2015
Acute myeloid leukemia: advancing clinical trials and promising therapeutics
artículo científico publicado en 2016
Acute promyelocytic leukemia: a population-based study on incidence and survival in the United States, 1975-2008.
artículo científico publicado en 2012
Acute pulmonary failure during remission induction chemotherapy in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2010
Adaptive randomized study of idarubicin and cytarabine alone or with interleukin-11 as induction therapy in patients aged 50 or above with acute myeloid leukemia or high-risk myelodysplastic syndromes
artículo científico publicado en 2005
Adaptive randomized study of idarubicin and cytarabine versus troxacitabine and cytarabine versus troxacitabine and idarubicin in untreated patients 50 years or older with adverse karyotype acute myeloid leukemia
artículo científico publicado en 2003
Addition of eltrombopag to immunosuppressive therapy in patients with newly diagnosed aplastic anemia
artículo científico publicado en 2018
Adherence to BCR-ABL inhibitors: issues for CML therapy
artículo científico publicado en 2012
Adult Acute Lymphoblastic Leukemia
artículo científico publicado en 2016
Adult acute lymphoblastic leukemia: concepts and strategies
artículo científico publicado en 2010
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at M.D. Anderson Cancer Center
artículo científico publicado en 2005
Adult acute myeloid leukemia
artículo científico publicado en 2006
Adults with acute lymphoblastic leukemia and translocation (1;19) abnormality have a favorable outcome with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with methotrexate and high-dose cytarabine chemot
artículo científico publicado en 2009
Advanced-phase chronic myeloid leukemia
artículo científico publicado en 2003
Advances in the biology and therapy of patients with chronic myeloid leukaemia
scientific article published on September 2009
Advances in the therapy of chronic idiopathic myelofibrosis
artículo científico publicado en 2006
Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
Alemtuzumab therapy for hypereosinophilic syndrome and chronic eosinophilic leukemia
artículo científico publicado en 2009
Alemtuzumab: validation of a sensitive and simple enzyme-linked immunosorbent assay.
artículo científico publicado en 2004
Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia
artículo científico publicado en 2016
Allogeneic hematopoietic stem cell transplantation versus hypomethylating agents in patients with myelodysplastic syndrome: a retrospective case-control study
artículo científico publicado en 2013
Allogeneic stem cell transplantation as initial salvage for patients with acute myeloid leukemia refractory to high-dose cytarabine-based induction chemotherapy
artículo científico publicado en 2014
Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
artículo científico publicado en 2006
Amifostine does not reduce the toxicity of the fludarabine and cyclophosphamide regimen in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
Amphotericin B lipid complex as prophylaxis of invasive fungal infections in patients with acute myelogenous leukemia and myelodysplastic syndrome undergoing induction chemotherapy
artículo científico publicado en 2004
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia
artículo científico publicado en 2012
An accurate, simple prognostic model consisting of age, JAK2, CALR, and MPL mutation status for patients with primary myelofibrosis
artículo científico publicado en 2016
An exploratory clinical trial of bortezomib in patients with lower risk myelodysplastic syndromes
artículo científico publicado en 2017
An immunological method for the detection of BCR-ABL fusion protein and monitoring its activation
artículo científico publicado en 2007
An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
scientific article published on 01 April 2019
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders
artículo científico publicado en 2003
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
artículo científico publicado en 2016
Analysis of Aurora kinase A expression in CD34(+) blast cells isolated from patients with myelodysplastic syndromes and acute myeloid leukemia
artículo científico publicado en 2008
Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs
Analysis of outcomes in adolescents and young adults with chronic myelogenous leukemia treated with upfront tyrosine kinase inhibitor therapy
artículo científico publicado en 2012
Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase
artículo científico publicado en 2003
Analysis of the potential effect of ponatinib on the QTc interval in patients with refractory hematological malignancies
artículo científico publicado en 2013
Anaplastic large cell lymphoma with involvement of the pancreas presenting as panniculitis in a patient with a history of acute myeloid leukemia--case report and review of the literature.
artículo científico publicado en 2006
Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen
artículo científico publicado en 2010
Anti-leukemia activity of NSC-743380 in SULT1A1-expressing acute myeloid leukemia cells is associated with inhibitions of cFLIP expression and PI3K/AKT/mTOR activities
artículo científico publicado en 2017
Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia
artículo científico publicado en 2017
Antileukemia activity of the combination of 5-aza-2'-deoxycytidine with valproic acid
artículo científico publicado en 2005
Apoptosis repressor with caspase recruitment domain modulates second mitochondrial-derived activator of caspases mimetic-induced cell death through BIRC2/MAP3K14 signalling in acute myeloid leukaemia
artículo científico publicado en 2014
Applying cytogenetic and molecular information in the clinic: implications for the treatment of chronic myeloid leukemia
artículo científico publicado en 2010
Are high drug prices for hematologic malignancies justified? A critical analysis
artículo científico
Arsenic derivatives in hematologic malignancies: a role beyond acute promyelocytic leukemia?
artículo científico publicado en 2006
Artificial Intelligence, Big Data, and Cancer
artículo científico publicado en 2015
Aspergillus terreus: an emerging amphotericin B-resistant opportunistic mold in patients with hematologic malignancies
artículo científico publicado en 2004
Assessment at 6 months may be warranted for patients with chronic myeloid leukemia with no major cytogenetic response at 3 months
artículo científico publicado en 2013
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas M.D. Anderson Cancer Center
artículo científico publicado en 2007
Association of anemia and cognitive dysfunction in patients with acute myelogenous leukemia and myelodysplastic syndrome
artículo científico publicado en 2011
Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
artículo científico publicado en 2018
Association of comorbidities with overall survival in myelodysplastic syndrome: development of a prognostic model
artículo científico publicado en 2011
Association of lymphoid malignancies and Philadelphia-chromosome negative myeloproliferative neoplasms: Clinical characteristics, therapy and outcome
artículo científico publicado en 2015
Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells
artículo científico publicado en 2006
Augmented Berlin-Frankfurt-Münster therapy in adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).
artículo científico publicado en 2014
Augmented hyper-CVAD based on dose-intensified vincristine, dexamethasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy
artículo científico publicado en 2011
BCR-ABL alternative splicing as a common mechanism for imatinib resistance: evidence from molecular dynamics simulations
artículo científico publicado en 2008
BCR-ABL fusion transcript types and levels and their interaction with secondary genetic changes in determining the phenotype of Philadelphia chromosome-positive leukemias
artículo científico publicado en 2008
BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors
artículo científico publicado en 2009
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
scientific article published on March 2008
BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia
artículo científico publicado en 2014
BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.
artículo científico publicado en 2014
Bafetinib, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia
artículo científico publicado en 2010
Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome
artículo científico publicado en 2004
Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders
artículo científico publicado en 2004
Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
artículo científico publicado en 2008
Biological and clinical features of trisomy 21 in adult patients with acute myeloid leukemia
artículo científico publicado en 2013
Biology and treatment of chronic myelogenous leukemia
artículo científico publicado el 1 de septiembre de 1997
Biosimilar and generic cancer drugs unlikely to bend cost curve in the USA.
artículo científico publicado en 2017
Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy
artículo científico publicado en 2009
Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia
artículo científico publicado en 2019
Blinatumomab treatment of older adults with relapsed/refractory B-precursor acute lymphoblastic leukemia: Results from 2 phase 2 studies
artículo científico publicado en 2016
Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia
artículo científico publicado en 2017
Blood counts at time of complete remission provide additional independent prognostic information in acute myeloid leukemia
artículo científico publicado en 2008
Bone marrow cyclooxygenase-2 levels are elevated in chronic-phase chronic myeloid leukaemia and are associated with reduced survival
artículo científico publicado en 2002
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosis
scientific article published on 23 January 2013
Bone marrow necrosis in acute leukemia: Clinical characteristic and outcome
artículo científico publicado en 2015
Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor
artículo científico publicado en 2011
Bosutinib efficacy and safety in chronic phase chronic myeloid leukemia after imatinib resistance or intolerance: Minimum 24-month follow-up
artículo científico publicado en 2014
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
scientific article published on 27 February 2012
Bosutinib safety and management of toxicity in leukemia patients with resistance or intolerance to imatinib and other tyrosine kinase inhibitors
artículo científico publicado en 2013
Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial
artículo científico publicado en 2012
Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias
scientific article published on 27 September 2016
Burden of hospitalization in acute lymphoblastic leukemia patients treated with Inotuzumab Ozogamicin versus standard chemotherapy treatment
scientific article published on 22 August 2019
Burkitt lymphoma and atypical Burkitt or Burkitt-like lymphoma: should these be treated as different diseases?
artículo científico publicado en 2011
C-kit receptor expression in acute leukemias-association with patient and disease characteristics and with outcome
artículo científico publicado en 2004
CCL3 (MIP-1α) plasma levels and the risk for disease progression in chronic lymphocytic leukemia
⬇️
artículo científico publicado el 29 de noviembre de 2010
CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma
artículo científico publicado en 2015
CD105 (endoglin) is highly overexpressed in a subset of cases of acute myeloid leukemias
artículo científico publicado en 2013
CD123 expression patterns and selective targeting with a CD123-specific antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia
scholarly article by Evgeniya Angelova et al published 25 October 2018 in Haematologica
CD33 is frequently expressed in cases of myelodysplastic syndrome and chronic myelomonocytic leukemia with elevated blast count
artículo científico publicado en 2016
CD56 expression predicts occurrence of CNS disease in acute lymphoblastic leukemia
artículo científico publicado en 2002
CDDO induces granulocytic differentiation of myeloid leukemic blasts through translational up-regulation of p42 CCAAT enhancer binding protein alpha
artículo científico publicado en 2007
CXC chemokine receptor 4 expression, CXC chemokine receptor 4 activation, and wild-type nucleophosmin are independently associated with unfavorable prognosis in patients with acute myeloid leukemia
artículo científico publicado en 2013
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
artículo científico publicado en 2008
Cancer Drugs: An International Comparison of Postlicensing Price Inflation
artículo científico publicado en 2017
Cancer Genomics in Clinical Context
artículo científico publicado en 2015
Cancer research in the United States: A critical review of current status and proposal for alternative models
scientific article published on 14 May 2018
Cancer research in the United States: dying by a thousand paper cuts
artículo científico publicado en 2013
Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia
artículo científico publicado en 2005
Case series of patients with acute myeloid leukemia receiving hypomethylation therapy and retrospectively found to have IDH1 or IDH2 mutations
artículo científico publicado en 2013
Cause of death in patients with lower-risk myelodysplastic syndrome
artículo científico publicado en 2010
Cellular signalling pathways: new targets in leukaemia therapy
artículo científico publicado en 2002
Central nervous system prophylaxis in adults with acute lymphoblastic leukemia: current and emerging therapies
artículo científico publicado en 2010
Central nervous system relapse in adults with acute lymphoblastic leukemia
artículo científico publicado en 2002
Changes associated with the development of resistance to imatinib (STI571) in two leukemia cell lines expressing p210 Bcr/Abl protein
artículo científico publicado en 2004
Characteristics and outcome of chronic myeloid leukemia patients with E255K/V BCR-ABL kinase domain mutations
artículo científico publicado en 2018
Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
artículo científico publicado en 2008
Characteristics and outcome of patients with acute myeloid leukemia refractory to 1 cycle of high-dose cytarabine-based induction chemotherapy
artículo científico publicado en 2010
Characteristics and outcome of respiratory syncytial virus infection in patients with leukemia
artículo científico publicado en 2007
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach
artículo científico publicado en 2017
Characteristics and outcomes of patients with V299L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors
artículo científico publicado en 2012
Characteristics and outcomes of patients with chronic myeloid leukemia and T315I mutation following failure of imatinib mesylate therapy
artículo científico publicado en 2008
Characteristics and outcomes of patients with multiple myeloma who develop therapy-related myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia
artículo científico publicado en 2014
Characteristics associated with important clinical end points in patients with chronic lymphocytic leukemia at initial treatment
artículo científico publicado en 2009
Characteristics of Sweet Syndrome in patients with acute myeloid leukemia
artículo científico publicado en 2014
Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys
artículo científico publicado en 2008
Characteristics of patients with myeloproliferative neoplasms with lymphoma, with or without JAK inhibitor therapy
artículo científico publicado en 2019
Characteristics of pericardial effusions in patients with leukemia
artículo científico publicado en 2010
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemia
artículo científico publicado en 2012
Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML
artículo científico publicado en 2015
Chemical and clinical development of darinaparsin, a novel organic arsenic derivative
artículo científico publicado en 2008
Chemoimmunotherapy may overcome the adverse prognostic significance of 11q deletion in previously untreated patients with chronic lymphocytic leukemia
artículo científico publicado en 2009
Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia
artículo científico publicado en 2010
Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia
artículo científico publicado en 2005
Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia
artículo científico publicado en 2006
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini-hyper-CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage
scientific article published on 11 October 2018
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
artículo científico publicado en 2007
Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2003
Chromosome 5q deletion is extremely rare in patients with myelofibrosis
artículo científico publicado en 2013
Chronic Myelogenous Leukemia: Disease Biology and Current and Future Therapeutic Strategies.
artículo científico publicado en 2000
Chronic myelogenous leukemia in T cell lymphoid blastic phase achieving durable complete cytogenetic and molecular remission with imatinib mesylate (STI571; Gleevec) therapy
artículo científico publicado en 2002
Chronic myelogenous leukemia: a review and update of therapeutic strategies
artículo científico publicado en 2003
Chronic myelogenous leukemia: update on biology and treatment
artículo científico publicado en 1999
Chronic myeloid leukemia (CML) with P190 BCR-ABL: analysis of characteristics, outcomes, and prognostic significance
artículo científico publicado en 2009
Chronic myeloid leukemia among patients with a history of prior malignancies: A tale of dual survivorship
artículo científico publicado en 2016
Chronic myeloid leukemia and second-generation tyrosine kinase inhibitors: when, how, and which one?
artículo científico publicado en 2010
Chronic myeloid leukemia in a patient with acquired immune deficiency syndrome: complete cytogenetic response with imatinib mesylate: report of a case and review of the literature
artículo científico publicado en 2004
Chronic myeloid leukemia in the tyrosine kinase inhibitor era: what is the "best" therapy?
artículo científico publicado en 2010
Chronic myeloid leukemia: 2012 update on diagnosis, monitoring, and management
artículo científico publicado en 2012
Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management
artículo científico publicado en 2014
Chronic myeloid leukemia: 2016 update on diagnosis, therapy, and monitoring
artículo científico publicado en 2016
Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring
artículo científico publicado en 2018
Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring
artículo científico publicado en 2020
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
artículo científico publicado en 2009
Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment
artículo científico publicado en 2005
Chronic myeloid leukemia: mechanisms of resistance and treatment
artículo científico publicado en 2011
Chronic myeloid leukemia: overview of new agents and comparative analysis
artículo científico
Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia
artículo científico publicado en 2017
Circulating CD20 and CD52 in patients with non-Hodgkin's lymphoma or Hodgkin's disease
scientific article published on 01 December 2003
Circulating CD33 and its clinical value in acute leukemia
artículo científico publicado en 2010
Circulating CD52 and CD20 levels at end of treatment predict for progression and survival in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab (FCR).
artículo científico publicado en 2009
Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia
artículo científico publicado en 2010
Circulating Ki-67 protein in plasma as a biomarker and prognostic indicator of acute lymphoblastic leukemia
artículo científico publicado en 2009
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia
artículo científico publicado en 2008
Circulating levels and clinical significance of soluble CD40 in patients with hematologic malignancies
artículo científico publicado en 2006
Cladribine and low-dose cytarabine alternating with decitabine as front-line therapy for elderly patients with acute myeloid leukaemia: a phase 2 single-arm trial
scientific article published on 13 August 2018
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
artículo científico publicado en 2018
Clinical Experience of Venetoclax Combinations for Relapsed/Refractory Myeloid Malignancies
artículo científico publicado en 2017
Clinical Outcomes and Co-Occurring Mutations in Patients with RUNX1-Mutated Acute Myeloid Leukemia
artículo científico publicado en 2017
Clinical Outcomes and Influence of Mutation Clonal Dominance in Oligomonocytic and Classical Chronic Myelomonocytic Leukemia
artículo científico publicado en 2020
Clinical Outcomes in Adult Patients with Aplastic Anemia- a single institution experience
artículo científico
Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients With Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and/or Renal Dysfunction
artículo científico publicado en 2015
Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action
artículo científico publicado en 2004
Clinical activity of ponatinib in patients with chronic myeloid leukemia in chronic phase with e1a2 transcripts
artículo científico publicado en 2013
Clinical activity of tipifarnib in hematologic malignancies
artículo científico publicado en 2007
Clinical algorithms for the treatment of patients with chronic myeloid leukemia: the 2010 perspective
artículo científico publicado en 2010
Clinical and molecular characteristics of XPO1 mutations in patients with chronic lymphocytic leukemia
artículo científico publicado en 2016
Clinical and prognostic significance of 3q26.2 and other chromosome 3 abnormalities in CML in the era of tyrosine kinase inhibitors
artículo científico publicado en 2015
Clinical and proteomic characterization of acute myeloid leukemia with mutated RAS.
artículo científico publicado en 2012
Clinical characteristics and outcomes in patients with acute myeloid leukemia with concurrent FLT3-ITD and IDH mutations
scientific article published on 29 October 2020
Clinical characteristics and outcomes in patients with acute promyelocytic leukaemia and hyperleucocytosis
artículo científico publicado en 2014
Clinical characteristics and outcomes of previously untreated patients with adult onset T-acute lymphoblastic leukemia and T-lymphoblastic lymphoma with hyper-CVAD based regimens
artículo científico publicado en 2017
Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia
scientific article published on 29 July 2013
Clinical characteristics of Philadelphia positive T-cell lymphoid leukemias-(De novo and blast phase CML).
artículo científico publicado en 2016
Clinical correlation of circulating heat shock protein 70 in acute leukemia
artículo científico publicado en 2009
Clinical development of farnesyltransferase inhibitors in leukemias and myelodysplastic syndrome
artículo científico publicado en 2002
Clinical effect of point mutations in myelodysplastic syndromes
artículo científico publicado en 2011
Clinical experience with decitabine in North American patients with myelodysplastic syndrome
artículo científico publicado en 2005
Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies
artículo científico publicado en 2017
Clinical features of de novo acute myeloid leukemia with concurrent DNMT3A, FLT3 and NPM1 mutations
artículo científico publicado en 2014
Clinical impact of change of FLT3 mutation status in acute myeloid leukemia patients.
artículo científico publicado en 2012
Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia
artículo científico publicado en 2010
Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
artículo científico publicado en 2016
Clinical implications of cancer gene mutations in patients with chronic lymphocytic leukemia treated with lenalidomide
artículo científico publicado en 2018
Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation
artículo científico publicado en 2006
Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma
artículo científico publicado en 2004
Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease
scientific article published on 20 March 2006
Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms
scientific article published in Nature Communications
Clinical significance of microcytosis in patients with primary myelofibrosis
artículo científico publicado en 2014
Clinical use of ruxolitinib in an academic medical center in unselected patients with myeloproliferative neoplasms not on clinical study
artículo científico publicado en 2016
Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients
artículo científico publicado en 2015
Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50 years of age or older
artículo científico publicado en 2006
Clofarabine combinations as acute myeloid leukemia salvage therapy
artículo científico publicado en 2008
Clofarabine does not negatively impact the outcomes of patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation
artículo científico publicado en 2012
Clofarabine for the treatment of acute lymphoblastic leukemia
artículo científico publicado en 2007
Clofarabine in adult acute leukemias: clinical success and pharmacokinetics
artículo científico publicado en 2004
Clofarabine in leukemia
artículo científico publicado en 2010
Clofarabine in the treatment of myelodysplastic syndromes
artículo científico publicado en 2014
Clofarabine plus cytarabine compared with cytarabine alone in older patients with relapsed or refractory acute myelogenous leukemia: results from the CLASSIC I Trial
artículo científico publicado en 2012
Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients
scientific article published on 26 January 2012
Clofarabine with high dose cytarabine and granulocyte colony-stimulating factor (G-CSF) priming for relapsed and refractory acute myeloid leukaemia
artículo científico publicado en 2011
Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia
⬇️
artículo científico publicado el 9 de octubre de 2003
Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2013
Clofarabine: emerging role in leukemias
artículo científico publicado en 2009
Clofarabine: past, present, and future
artículo científico publicado en 2007
Clonal Evolution and Treatment Outcomes in Hematopoietic Neoplasms Arising in Patients with Germline RUNX1 mutations
scientific article published on 17 August 2020
Clonal chromosomal abnormalities appearing in Philadelphia chromosome-negative metaphases during CML treatment
artículo científico publicado en 2017
Clonal evolution and outcomes in myelofibrosis after ruxolitinib discontinuation
artículo científico publicado en 2017
Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition
artículo científico publicado en 2016
Clonal evolution of acute myeloid leukemia relapsed after 19 years of remission
artículo científico publicado en 2015
Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
artículo científico publicado en 2020
Clonal hematopoiesis of indeterminate potential-associated mutations and risk of comorbidities in patients with myelodysplastic syndrome
artículo científico publicado en 2019
Co-occurrence of CRLF2-rearranged and Ph+ acute lymphoblastic leukemia: a report of four patients
artículo científico publicado en 2017
Coalesced multicentric analysis of 2,351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system
artículo científico publicado en 2011
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study
artículo científico publicado en 2015
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
scientific article published on 01 December 2018
Combined targeting of BCL-2 and BCR-ABL tyrosine kinase eradicates chronic myeloid leukemia stem cells
artículo científico publicado en 2016
Combining Anti-Mir-155 with Chemotherapy for the Treatment of Lung Cancers
artículo científico publicado en 2016
Comment on "Chromosomal instability and tumors promoted by DNA hypomethylation" and "Induction of tumors in nice by genomic hypomethylation".
artículo científico publicado en 2003
Comparative analysis of genes regulated in acute myelomonocytic leukemia with and without inv(16)(p13q22) using microarray techniques, real-time PCR, immunohistochemistry, and flow cytometry immunophenotyping.
artículo científico publicado en 2007
Comparison of thalidomide and lenalidomide as therapy for myelofibrosis
artículo científico publicado en 2011
Comparison of two different schedules of granulocyte-colony-stimulating factor during treatment for acute lymphocytic leukemia with a hyper-CVAD (cyclophosphamide, doxorubicin, vincristine, and dexamethasone) regimen
artículo científico publicado en 2002
Competing cell clones in myeloproliferative neoplasm
artículo científico publicado en 2010
Complete cytogenetic and molecular responses to interferon-alpha-based therapy for chronic myelogenous leukemia are associated with excellent long-term prognosis
artículo científico publicado en 2003
Complete cytogenetic response, not deep molecular response, is associated with survival in chronic myeloid leukemia.
artículo científico publicado en 2014
Complete remission in a patient with JAK2- and IDH2-positive myelofibrosis
artículo científico publicado en 2016
Complex karyotype is a stronger predictor than del(17p) for an inferior outcome in relapsed or refractory chronic lymphocytic leukemia patients treated with ibrutinib-based regimens
artículo científico publicado en 2015
Complexity of BCR-ABL kinase domain mutations during the course of therapy with tyrosine kinase inhibitors in chronic myeloid leukemia
artículo científico publicado en 2009
Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients
artículo científico publicado en 2015
Comprehensive craniospinal radiation for controlling central nervous system leukemia
artículo científico publicado en 2014
Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
artículo científico publicado en 2012
Conditional survival in patients with chronic myeloid leukemia in chronic phase in the era of tyrosine kinase inhibitors
artículo científico publicado en 2015
Congestive heart failure is a rare event in patients receiving imatinib therapy
artículo científico publicado en 2007
Considerations in the management of patients with Philadelphia chromosome-positive chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
artículo científico publicado en 2011
Contract research organizations in oncology clinical research: Challenges and opportunities
artículo científico publicado en 2016
Contribution of β-2 microglobulin levels to the prognostic stratification of survival in patients with myelodysplastic syndrome (MDS)
⬇️
artículo científico publicado el 8 de mayo de 2003
Correlation of mutation profile and response in patients with myelofibrosis treated with ruxolitinib
artículo científico publicado en 2015
Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation
artículo científico publicado en 2009
Current and emerging treatment options in chronic myeloid leukemia
artículo científico publicado en 2007
Current and future management options for myelodysplastic syndromes
artículo científico publicado en 2010
Current evaluation of imatinib and allogeneic transplant in the treatment of chronic myeloid leukemia.
artículo científico publicado en 2003
Current event-free survival after sequential tyrosine kinase inhibitor therapy for chronic myeloid leukemia
artículo científico publicado en 2010
Current paradigms in the management of Philadelphia chromosome positive acute lymphoblastic leukemia in adults
artículo científico publicado en 2017
Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment
artículo científico publicado en 2007
Current therapy of chronic myelogenous leukemia.
artículo científico publicado en 2002
Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia
artículo científico publicado en 2011
Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
artículo científico publicado en 2009
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
artículo científico publicado en 2008
Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease
artículo científico publicado en 2011
Cytopenia levels for aiding establishment of the diagnosis of myelodysplastic syndromes
artículo científico publicado en 2016
Cytoplasmic localization of nucleophosmin in bone marrow blasts of acute myeloid leukemia patients is not completely concordant with NPM1 mutation and is not predictive of prognosis
artículo científico publicado en 2009
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease
scientific article published on 07 May 2019
DNA methylation in haematological malignancies: the role of decitabine
artículo científico publicado en 2003
DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia
artículo científico publicado en 2002
DNA methylation patterns at relapse in adult acute lymphocytic leukemia
artículo científico publicado en 2002
DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes
artículo científico publicado en 2009
Daily palonosetron is superior to ondansetron in the prevention of delayed chemotherapy-induced nausea and vomiting in patients with acute myelogenous leukemia
artículo científico publicado en 2010
Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia
artículo científico publicado en 2009
Dasatinib for the treatment of Philadelphia chromosome-positive leukaemias
artículo científico publicado en 2007
Dasatinib for the treatment of chronic myeloid leukemia
artículo científico publicado en 2011
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
artículo científico publicado en 2006
Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
artículo científico publicado en 2016
Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION).
artículo científico publicado en 2011
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia
artículo científico publicado en 2010
Decitabine and its role in the treatment of hematopoietic malignancies
artículo científico publicado en 2007
Decitabine can be safely reduced after achievement of best objective response in patients with myelodysplastic syndrome
artículo científico publicado en 2013
Decitabine improves outcomes in older patients with acute myeloid leukemia and higher blast counts
artículo científico publicado en 2015
Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study
artículo científico publicado en 2006
Decitabine improves response rate and prolongs progression-free survival in older patients with newly diagnosed acute myeloid leukemia and with monosomal karyotype: A subgroup analysis of the DACO-016 trial
artículo científico publicado en 2018
Decitabine in older adults with acute myeloid leukemia: why was the dream broken?
artículo científico publicado en 2013
Decitabine in the treatment of myelodysplastic syndromes.
artículo científico publicado en 2010
Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration
⬇️
artículo científico publicado el 24 de agosto de 2010
Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy
scientific article published on 15 April 2009
Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia
artículo científico publicado en 2016
Design, development, and validation of a high-throughput drug-screening assay for targeting of human leukemia
artículo científico publicado en 2013
Detectable FLT3-ITD or RAS mutation at the time of transformation from MDS to AML predicts for very poor outcomes
artículo científico publicado en 2015
Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy
artículo científico publicado en 2013
Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis
artículo científico publicado en 2012
Detection of nucleophosmin gene mutations in plasma from patients with acute myeloid leukemia: clinical significance and implications.
artículo científico publicado en 2009
Development and targeted use of nilotinib in chronic myeloid leukemia.
artículo científico publicado en 2009
Development and validation of a model to predict platelet response to romiplostim in patients with lower-risk myelodysplastic syndromes
artículo científico publicado en 2014
Diagnosis and Treatment of Chronic Myeloid Leukemia in 2015.
artículo científico
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns
artículo científico publicado en 2007
Diagnostic Challenges of Hemophagocytic Lymphohistiocytosis
artículo científico publicado en 2017
Differential effects of dosing regimen on the safety and efficacy of dasatinib: retrospective exposure-response analysis of a Phase III study
artículo científico publicado en 2013
Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia
artículo científico publicado en 2016
Differing clinical features between Japanese and Caucasian patients with myelodysplastic syndromes: Analysis from the International Working Group for Prognosis of MDS
scientific article published on 06 September 2018
Digital image analysis as a tool to assess the effects of imatinib on trabecular bone in patients with chronic myelogenous leukemia
artículo científico publicado en 2012
Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up
artículo científico publicado en 2015
Discontinuation of imatinib therapy after achieving a molecular response
artículo científico publicado en 2004
Discrepancy in diagnosis of primary myelofibrosis between referral and tertiary care centers
artículo científico publicado en 2013
Dorsal column myelopathy after intrathecal chemotherapy for leukemia
artículo científico publicado en 2016
Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia
artículo científico publicado en 2002
Dose, schedule, safety, and efficacy of guadecitabine in relapsed or refractory acute myeloid leukemia.
artículo científico publicado en 2017
Double inv(3)(q21q26.2) in acute myeloid leukemia is resulted from an acquired copy neutral loss of heterozygosity of chromosome 3q and associated with disease progression
artículo científico publicado en 2015
Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion
artículo científico publicado en 2015
Dynamic model for predicting death within 12 months in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
artículo científico publicado en 2009
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
artículo científico publicado en 2009
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
artículo científico publicado en 2011
EUTOS score is not predictive for survival and outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors: a single institution experience
artículo científico publicado en 2012
EXEL-0862, a novel tyrosine kinase inhibitor, induces apoptosis in vitro and ex vivo in human mast cells expressing the KIT D816V mutation
artículo científico publicado en 2006
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy
artículo científico publicado en 2019
Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype
artículo científico publicado en 2016
Early cytogenetic and molecular response during first-line treatment of chronic myeloid leukemia in chronic phase: long-term implications
artículo científico publicado en 2011
Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib
artículo científico publicado en 2013
Early response with dasatinib or imatinib in chronic myeloid leukemia: 3-year follow-up from a randomized phase 3 trial (DASISION).
artículo científico publicado en 2013
Early responses predict better outcomes in patients with newly diagnosed chronic myeloid leukemia: results with four tyrosine kinase inhibitor modalities
artículo científico publicado en 2013
Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia
artículo científico publicado en 2005
Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
artículo científico publicado en 2018
Economic Burden of Chronic Lymphocytic Leukemia in the Era of Oral Targeted Therapies in the United States
artículo científico publicado en 2016
Effect of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy
artículo científico publicado en 2013
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML.
artículo científico publicado en 2003
Effect of complete remission and responses less than complete remission on survival in acute myeloid leukemia: a combined Eastern Cooperative Oncology Group, Southwest Oncology Group, and M. D. Anderson Cancer Center Study
artículo científico publicado en 2010
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
artículo científico publicado en 2013
Effect of the tyrosine kinase inhibitor nilotinib in patients with hypereosinophilic syndrome/chronic eosinophilic leukemia: analysis of the phase 2, open-label, single-arm A2101 study
artículo científico publicado en 2013
Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin
artículo científico publicado en 2008
Effectiveness of homoharringtonine (omacetaxine mepesuccinate) for treatment of acute myeloid leukemia: a meta-analysis of Chinese studies
artículo científico
Effects of AMN107, a novel aminopyrimidine tyrosine kinase inhibitor, on human mast cells bearing wild-type or mutated codon 816 c-kit
artículo científico publicado en 2006
Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias
artículo científico
Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia
artículo científico publicado en 2012
Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia
artículo científico publicado en 2003
Effects of clinically relevant MPL mutations in the transmembrane domain revealed at the atomic level through computational modeling
artículo científico publicado en 2011
Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia
artículo científico publicado en 2016
Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL
scientific article published on 01 May 2019
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE.
artículo científico publicado en 2018
Efficacy and safety of generic imatinib after switching from original imatinib in patients treated for chronic myeloid leukemia in the United States
artículo científico publicado en 2019
Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2009
Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies
artículo científico publicado en 2003
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2009
Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome
artículo científico publicado en 2003
Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia
scientific article published on 24 November 2020
Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies
artículo científico publicado en 2002
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Non-randomized, Open-label, Phase 2 Study
artículo científico publicado en 2018
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I.
artículo científico publicado en 2013
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I.
artículo científico publicado en 2015
Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia
⬇️
artículo científico publicado el 22 de marzo de 2011
Emerging drugs for acute lymphocytic leukemia
artículo científico
Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors
artículo científico publicado en 2007
Emerging therapy for the treatment of acute lymphoblastic leukemia
artículo científico publicado en 2010
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AML.
artículo científico publicado en 2003
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2017
Enzymatic activity of circulating proteasomes correlates with clinical behavior in patients with chronic lymphocytic leukemia
artículo científico publicado en 2008
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2012
Epigenetics of acute lymphocytic leukemia
artículo científico publicado en 2009
Epoetin alpha decreases the number of erythrocyte transfusions in patients with acute lymphoblastic leukemia, lymphoblastic lymphoma, and Burkitt leukemia/lymphoma: results of a randomized clinical trial
scientific article published on 12 July 2011
Eradication of minimal residual disease in hairy cell leukemia
artículo científico publicado en 2006
Erratum: Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase
scholarly article published in Cancer
Erythropoietin is effective in improving the anemia induced by imatinib mesylate therapy in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2004
Establishment of baseline toxicity expectations with standard frontline chemotherapy in acute myelogenous leukemia
artículo científico
Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors
artículo científico publicado en 2015
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
artículo científico publicado en 2012
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
artículo científico publicado en 2013
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial
artículo científico publicado en 2011
Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies
artículo científico publicado en 2008
Evolution of therapies for chronic myelogenous leukemia
artículo científico publicado en 2011
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
artículo científico publicado en 2006
Expectations of serious adverse events at the end of life of patients with acute myeloid leukemia who receive salvage therapy
artículo científico publicado en 2013
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
artículo científico publicado en 2003
Experience with everolimus (RAD001), an oral mammalian target of rapamycin inhibitor, in patients with systemic mastocytosis
artículo científico publicado en 2010
Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia
artículo científico publicado en 2002
Experimental therapeutics for patients with myeloproliferative neoplasias
artículo científico publicado en 2010
Experimental therapy in myelofibrosis with myeloid metaplasia
artículo científico publicado en 2006
Expression of ARC (apoptosis repressor with caspase recruitment domain), an antiapoptotic protein, is strongly prognostic in AML
artículo científico publicado en 2010
Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia
artículo científico publicado en 2004
Extramedullary relapse in a patient with acute promyelocytic leukemia: successful treatment with arsenic trioxide, all-trans retinoic acid and gemtuzumab ozogamicin therapies
artículo científico publicado en 2004
FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia
artículo científico publicado en 2014
FLT3 inhibitors in the treatment of acute myeloid leukemia: the start of an era?
artículo científico publicado en 2011
FLT3 mutation and response to intensive chemotherapy in young adult and elderly patients with normal karyotype
artículo científico publicado en 2004
FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia
artículo científico publicado en 2012
Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia
artículo científico publicado en 2017
Factors influencing long-term efficacy and tolerability of bosutinib in chronic phase chronic myeloid leukaemia resistant or intolerant to imatinib
artículo científico publicado en 2015
Failure of hypomethylating agent-based therapy in myelodysplastic syndromes
artículo científico publicado en 2011
Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast
artículo científico publicado en 2009
Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia
artículo científico publicado en 2008
Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting
artículo científico publicado en 2003
Farnesyltransferase inhibitors: novel compounds in development for the treatment of myeloid malignancies
artículo científico publicado en 2002
Fatal hepatic veno-occlusive disease in a phase I study of mylotarg and troxatyl in patients with refractory acute myeloid leukemia or myelodysplastic syndrome
artículo científico publicado en 2002
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment
artículo científico publicado en 2007
Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin
artículo científico publicado en 2013
Feasibility of therapy with hypomethylating agents in patients with renal insufficiency
artículo científico publicado en 2010
Final 5-Year Study Results of DASISION: The Dasatinib Versus Imatinib Study in Treatment-Naïve Chronic Myeloid Leukemia Patients Trial
artículo científico publicado en 2016
Final analysis of the efficacy and safety of omacetaxine mepesuccinate in patients with chronic- or accelerated-phase chronic myeloid leukemia: Results with 24 months of follow-up
artículo científico publicado en 2015
Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2015
Final results of a phase 2 trial of clofarabine and low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2015
Final results of a phase 2, open-label study of indisulam, idarubicin, and cytarabine in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
artículo científico publicado en 2018
Final results of a single institution experience with a pediatric-based regimen, the augmented Berlin-Frankfurt-Münster, in adolescents and young adults with acute lymphoblastic leukemia, and comparison to the hyper-CVAD regimen
artículo científico publicado en 2016
Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome
artículo científico publicado en 2012
First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia
artículo científico publicado en 2010
First-line therapy for chronic myeloid leukemia: Past, present, and future
artículo científico publicado en 2009
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia
artículo científico publicado en 2004
Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL.
artículo científico publicado en 2011
Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia
artículo científico publicado en 2015
Flying under the radar: the new wave of BCR-ABL inhibitors
artículo científico publicado en 2007
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophage-colony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients wit
artículo científico publicado en 2003
Frequent deletions at 12q14.3 chromosomal locus in adult acute lymphoblastic leukemia.
artículo científico publicado en 2005
Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia
artículo científico publicado en 2011
Front-line therapy with second-generation tyrosine kinase inhibitors in patients with early chronic phase chronic myeloid leukemia: what is the optimal response?
artículo científico publicado en 2011
Frontline therapy with high-dose imatinib versus second generation tyrosine kinase inhibitor in patients with chronic-phase chronic myeloid leukemia - a propensity score analysis
artículo científico publicado en 2016
Frontline treatment of acute myeloid leukemia in adults
artículo científico publicado en 2016
Functional proteomic profiling of AML predicts response and survival
artículo científico publicado en 2008
Future clinical implications for farnesyltransferase inhibitors in hematologic malignancies
artículo científico publicado en 2002
GATA3 rs3824662A allele is associated with CRLF2 rearranged B-cell acute lymphoblastic leukemia in adults and adolescents and young adults (AYAs) and is associated with poor prognosis
artículo científico publicado en 2020
Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia
artículo científico publicado en 2014
Gemtuzumab ozogamicin with or without interleukin 11 in patients 65 years of age or older with untreated acute myeloid leukemia and high-risk myelodysplastic syndrome: comparison with idarubicin plus continuous-infusion, high-dose cytosine arabinosi
artículo científico publicado en 2002
Gemtuzumab ozogamicin, fludarabine, cytarabine and cyclosporine combination regimen in patients with CD33+ primary resistant or relapsed acute myeloid leukemia
artículo científico publicado en 2003
Gemtuzumab ozogamicin: time to resurrect?
artículo científico publicado en 2012
Gemtuzumab, fludarabine, cytarabine, and cyclosporine in patients with newly diagnosed acute myelogenous leukemia or high-risk myelodysplastic syndromes
artículo científico publicado en 2003
Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome
artículo científico publicado en 2012
Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias
artículo científico publicado en 2010
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies
artículo científico publicado en 2009
Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia
artículo científico publicado en 2016
Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
artículo científico publicado en 2020
Granulocyte-colony-stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase chronic myelogenous leukemia
artículo científico publicado en 2004
Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia
artículo científico publicado en 2003
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
scientific article published on 03 May 2019
Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial
artículo científico publicado en 2017
HCVAD plus imatinib or dasatinib in lymphoid blastic phase chronic myeloid leukemia
artículo científico publicado en 2013
HDM4 (HDMX) is widely expressed in adult pre-B acute lymphoblastic leukemia and is a potential therapeutic target
artículo científico publicado en 2006
Haploidentical transplantation for acute myeloid leukemia patients with minimal/measurable residual disease at transplantation
artículo científico publicado en 2019
Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
artículo científico publicado en 2017
Having "Skin in the Game" and Allowing Cross-Border Importation of Drugs to Lower High Prices of Cancer Drugs
artículo científico publicado en 2015
Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
artículo científico publicado en 2002
Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
artículo científico publicado en 2010
Hemophagocytic lymphohistiocytosis in adults: An under recognized entity
artículo científico publicado en 2016
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study
artículo científico publicado en 2017
Hepatitis C: When high drug prices preclude patient benefit
artículo científico publicado en 2018
High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults
artículo científico publicado en 2016
High cancer drug prices in the United States: reasons and proposed solutions
artículo científico publicado en 2014
High fluorescence in situ hybridization percentage of deletion 11q in patients with chronic lymphocytic leukemia is an independent predictor of adverse outcome
artículo científico publicado en 2015
High-dose imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: high rates of rapid cytogenetic and molecular responses
artículo científico publicado en 2009
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia
artículo científico publicado en 2003
High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome-negative acute lymphoblastic leukemia
artículo científico publicado en 2012
High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia
artículo científico publicado en 2017
High-throughput single-cell DNA sequencing of acute myeloid leukemia tumors with droplet microfluidics
article by Maurizio Pellegrino et al published September 2018 in Genome Research
Higher detection rate of JAK2 mutation using plasma.
artículo científico publicado en 2008
Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV).
artículo científico publicado en 2017
Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience.
artículo científico publicado en 2006
Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009.
artículo científico publicado en 2009
Homoharringtonine/omacetaxine mepesuccinate: the long and winding road to food and drug administration approval
scientific article published on 20 June 2013
Homologous recombination as a resistance mechanism to replication-induced double-strand breaks caused by the antileukemia agent CNDAC.
artículo científico publicado en 2010
How I treat newly diagnosed chronic phase CML
artículo científico publicado en 2012
How much of US health care spending provides direct care or benefit to patients?
artículo científico publicado en 2019
Hyper-CVAD plus nelarabine in newly diagnosed adult T-cell acute lymphoblastic leukemia and T-lymphoblastic lymphoma
artículo científico publicado en 2017
Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
artículo científico publicado en 2016
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial
artículo científico publicado en 2020
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone and highly active antiretroviral therapy for patients with acquired immunodeficiency syndrome-related Burkitt lymphoma/leukemia
artículo científico publicado en 2002
Hypocellular acute myeloid leukemia in adults: analysis of the clinical outcome of 123 patients
artículo científico publicado en 2011
Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia
artículo científico publicado en 2015
Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 study
artículo científico publicado en 2019
Imatinib and beyond--exploring the full potential of targeted therapy for CML.
artículo científico publicado en 2009
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
artículo científico publicado en 2003
Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and/or renal dysfunction
artículo científico publicado en 2010
Imatinib has limited therapeutic activity for hypereosinophilic syndrome patients with unknown or negative PDGFRalpha mutation status
artículo científico publicado en 2008
Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study
artículo científico publicado en 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase
artículo científico publicado en 2002
Imatinib mesylate causes hypopigmentation in the skin
artículo científico publicado en 2003
Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy
artículo científico publicado en 2008
Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results.
artículo científico publicado en 2002
Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001
artículo científico publicado en 2009
Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
artículo científico publicado en 2002
Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in the chronic phase: comparison with historic data
artículo científico publicado en 2003
Imatinib mesylate therapy in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia: high incidence of early complete and major cytogenetic responses
artículo científico publicado en 2002
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
artículo científico publicado en 2004
Imatinib therapy in a patient with suspected chronic neutrophilic leukemia and FIP1L1-PDGFRA rearrangement.
artículo científico publicado en 2013
Immune anaemias in patients with chronic lymphocytic leukaemia treated with fludarabine, cyclophosphamide and rituximab--incidence and predictors
artículo científico publicado en 2007
Immune modulation of minimal residual disease in early chronic phase chronic myelogenous leukemia: a randomized trial of frontline high-dose imatinib mesylate with or without pegylated interferon alpha-2b and granulocyte-macrophage colony-stimulatin
artículo científico publicado en 2010
Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors
artículo científico publicado en 2017
Immunotherapy based approaches in myelofibrosis
artículo científico
Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors
artículo científico publicado en 2016
Impact of CD33 and ABCB1 single nucleotide polymorphisms in patients with acute myeloid leukemia and advanced myeloid malignancies treated with decitabine plus gemtuzumab ozogamicin
scientific article published on 30 April 2020
Impact of TKI maintenance post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia
artículo científico publicado en 2020
Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents
artículo científico publicado en 2017
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes
artículo científico publicado en 2014
Impact of complete molecular response on survival in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2016
Impact of numerical variation in FMS-like tyrosine kinase receptor 3 internal tandem duplications on clinical outcome in normal karyotype acute myelogenous leukemia
artículo científico publicado en 2012
Impact of the number of mutations in survival and response outcomes to hypomethylating agents in patients with myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms.
artículo científico publicado en 2018
Impact of the variant allele frequency of ASXL1, DNMT3A, JAK2, TET2, TP53, and NPM1 on the outcomes of patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2019
Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia
artículo científico publicado en 2011
Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers
artículo científico publicado en 2011
Importance of minimal residual disease in hairy cell leukemia: monoclonal antibodies as a therapeutic strategy
artículo científico publicado en 2009
Important therapeutic targets in chronic myelogenous leukemia
artículo científico publicado en 2007
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
artículo científico publicado en 2012
Improvement in clinical outcome of FLT3 ITD mutated acute myeloid leukemia patients over the last one and a half decade
artículo científico publicado en 2015
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience
artículo científico publicado en 2014
Improving the detection of patients with inherited predispositions to hematologic malignancies using next-generation sequencing-based leukemia prognostication panels
scientific article published on 06 April 2018
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs
scientific article published on 23 July 2015
In vitro activity of dimethylarsinic acid against human leukemia and multiple myeloma cell lines
artículo científico publicado en 2003
Incidence and management of myelosuppression in patients with chronic- and accelerated-phase chronic myeloid leukemia treated with omacetaxine mepesuccinate
artículo científico publicado en 2015
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience
artículo científico publicado en 2009
Incidence of second malignancies in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
artículo científico publicado en 2019
Incidence of secondary neoplasms in patients with acute promyelocytic leukemia treated with all-trans retinoic acid plus chemotherapy or with all-trans retinoic acid plus arsenic trioxide
artículo científico publicado en 2014
Increased apoptosis in bone marrow B lymphocytes but not T lymphocytes in myelodysplastic syndrome
artículo científico publicado en 2003
Increased likelihood of post-polycythemia vera myelofibrosis in Ph-negative MPN patients with chromosome 12 abnormalities
artículo científico publicado en 2015
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemia
artículo científico publicado en 2003
Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia
artículo científico publicado en 2007
Infections in patients with aplastic anemia: experience at a tertiary care cancer center.
artículo científico publicado en 2003
Inhibition of mitochondrial metabolism by methyl-2-cyano-3,12-dioxooleana-1,9-diene-28-oate induces apoptotic or autophagic cell death in chronic myeloid leukemia cells
artículo científico publicado en 2008
Initial Report of a Phase I Study of LY2510924, Idarubicin, and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
⬇️
Initial experience with CMC-544 (inotuzumab ozogamicin) in pediatric patients with relapsed B-cell acute lymphoblastic leukemia
artículo científico publicado en 2013
Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotini
artículo científico publicado en 2012
Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia
artículo científico publicado en 2016
Inotuzumab ozogamicin in B-cell acute lymphoblastic leukemias and non-Hodgkin's lymphomas
artículo científico
Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphobl
scientific article published on 15 April 2019
Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study
artículo científico publicado en 2018
Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia
artículo científico
Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study
artículo científico publicado en 2019
Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study
artículo científico publicado en 2012
Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1.
artículo científico publicado en 2015
Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes
artículo científico publicado en 2018
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia
artículo científico publicado en 2010
Intensive chemotherapy is more effective than hypomethylating agents for the treatment of younger patients with myelodysplastic syndrome and elevated bone marrow blasts
scientific article published on 29 April 2019
Intensively timed combination chemotherapy for the induction of adult patients with acute myeloid leukemia: long-term follow-up of a phase 2 study
artículo científico publicado en 2010
Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)
artículo científico publicado en 2016
Interferon alpha therapy for patients with essential thrombocythemia: final results of a phase II study initiated in 1986
artículo científico publicado en 2005
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
artículo científico publicado en 2013
Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia
artículo científico publicado en 2004
Interleukin-7 receptor-α gene mutations are not detected in adult T-cell acute lymphoblastic leukemia
artículo científico publicado en 2014
Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia
artículo científico publicado en 2008
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).
artículo científico publicado en 2006
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2016
Intravenous itraconazole for prophylaxis of systemic fungal infections in patients with acute myelogenous leukemia and high-risk myelodysplastic syndrome undergoing induction chemotherapy
artículo científico publicado en 2004
Investigational FMS-like tyrosine kinase 3 inhibitors in treatment of acute myeloid leukemia
artículo científico publicado en 2014
Investigational strategies in chronic myelogenous leukemia
artículo científico publicado en 2004
Is there a standard induction regimen for patients with AML?
artículo científico publicado en 2013
JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms
⬇️
artículo científico publicado el 13 de agosto de 2010
JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia
artículo científico publicado en 2005
JAK2 p.V617F detection and allele burden measurement in peripheral blood and bone marrow aspirates in patients with myeloproliferative neoplasms
artículo científico publicado en 2013
Janus kinase 2 variants associated with the transformation of myeloproliferative neoplasms into acute myeloid leukemia
scientific article published on 27 February 2019
Janus kinase 2: a critical target in chronic myelogenous leukemia
artículo científico publicado en 2006
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond
artículo científico publicado en 2011
Jumping Translocations in Myeloid Malignancies Associated With Treatment Resistance and Poor Survival
artículo científico publicado en 2015
KIR gene haplotype: an independent predictor of clinical outcome in MDS patients
artículo científico publicado en 2016
Kinase domain point mutations in Philadelphia chromosome-positive acute lymphoblastic leukemia emerge after therapy with BCR-ABL kinase inhibitors
artículo científico publicado en 2008
Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib
artículo científico publicado en 2014
Kinetics of bone marrow blasts during induction and achievement of complete remission in acute myeloid leukemia
artículo científico publicado en 2008
Kit inhibitor APcK110 extends survival in an AML xenograft mouse model
artículo científico publicado en 2010
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells
artículo científico publicado en 2009
L-carnitine and Vitamin B Complex for the Treatment of Pegasparaginase-induced Hyperbilirubinemia.
artículo científico publicado en 2018
Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents
artículo científico publicado en 2014
Late relapse in acute myeloid leukemia (AML): clonal evolution or therapy-related leukemia?
scholarly article by Musa Yilmaz et al published 16 January 2019 in Blood Cancer Journal
Late relapses in acute myeloid leukemia: analysis of characteristics and outcome
artículo científico publicado en 2010
Lenalidomide induces long-lasting responses in elderly patients with chronic lymphocytic leukemia
artículo científico publicado en 2013
Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis
artículo científico publicado en 2009
Lenalidomide therapy in myelofibrosis with myeloid metaplasia
artículo científico publicado en 2006
Leukemia cell proliferation and death in chronic lymphocytic leukemia patients on therapy with the BTK inhibitor ibrutinib
artículo científico publicado en 2017
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
artículo científico publicado en 2021
Levels of miR-29b do not predict for response in patients with acute myelogenous leukemia treated with the combination of 5-azacytidine, valproic acid, and ATRA.
artículo científico publicado en 2011
Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting
artículo científico publicado en 2017
Liposomal Grb2 antisense oligodeoxynucleotide (BP1001) in patients with refractory or relapsed haematological malignancies: a single-centre, open-label, dose-escalation, phase 1/1b trial.
artículo científico publicado en 2018
Liposomal amphotericin B versus the combination of fluconazole and itraconazole as prophylaxis for invasive fungal infections during induction chemotherapy for patients with acute myelogenous leukemia and myelodysplastic syndrome
artículo científico publicado en 2003
Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
artículo científico publicado en 2017
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.
artículo científico publicado en 2016
Long-term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib
artículo científico publicado en 2016
Long-term durable remission by cladribine followed by rituximab in patients with hairy cell leukaemia: update of a phase II trial
artículo científico publicado en 2016
Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis.
artículo científico publicado en 2018
Long-term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
artículo científico publicado en 2015
Long-term efficacy and safety of dasatinib in patients with chronic myeloid leukemia in accelerated phase who are resistant to or intolerant of imatinib
scholarly article by Oliver Ottmann et al published 3 September 2018 in Blood Cancer Journal
Long-term evaluation of cardiac and vascular toxicity in patients with Philadelphia chromosome-positive leukemias treated with bosutinib
artículo científico publicado en 2016
Long-term experience with imatinib therapy in chronic phase chronic myelogenous leukemia--remarkable activity with room for improvement
artículo científico publicado en 2008
Long-term follow-up of a phase 2 study of chemotherapy plus dasatinib for the initial treatment of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico publicado en 2015
Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
artículo científico publicado en 2003
Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes
artículo científico publicado en 2011
Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia
scientific article published on 25 September 2019
Long-term follow-up of patients with hypereosinophilic syndrome treated with Alemtuzumab, an anti-CD52 antibody
artículo científico publicado en 2012
Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome
artículo científico publicado en 2006
Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical tr
artículo científico publicado en 2015
Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab
artículo científico publicado en 2016
Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations
artículo científico publicado en 2009
Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study
artículo científico publicado en 2014
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib
artículo científico publicado en 2017
Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors
artículo científico publicado en 2010
Long-term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls
artículo científico publicado en 2012
Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis
artículo científico publicado en 2021
Long-term patient-reported outcomes from an open-label safety and efficacy study of bosutinib in Philadelphia chromosome-positive chronic myeloid leukemia patients resistant or intolerant to prior therapy
artículo científico publicado en 2017
Long-term prognostic impact of the use of erythropoietic-stimulating agents in patients with chronic myeloid leukemia in chronic phase treated with imatinib
artículo científico publicado en 2010
Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) st
artículo científico publicado en 2014
Long-term results of a phase 2 trial of nilotinib 400 mg twice daily in newly diagnosed patients with chronic-phase chronic myeloid leukemia
artículo científico publicado en 2020
Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis
artículo científico publicado en 2016
Long-term results of first salvage treatment in CLL patients treated initially with FCR (fludarabine, cyclophosphamide, rituximab)
artículo científico publicado en 2014
Long-term results of frontline dasatinib in chronic myeloid leukemia
scientific article published on 30 January 2020
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
scientific article published on 14 April 2008
Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial
artículo científico publicado en 2004
Long-term survival benefit and improved complete cytogenetic and molecular response rates with imatinib mesylate in Philadelphia chromosome-positive chronic-phase chronic myeloid leukemia after failure of interferon-alpha
artículo científico publicado en 2004
Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab
artículo científico publicado en 2020
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
artículo científico publicado en 2017
Low frequency of H3.3 mutations and upregulated DAXX expression in MDS.
artículo científico publicado en 2013
Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
artículo científico publicado en 2009
Low-level expression of SAMHD1 in acute myeloid leukemia (AML) blasts correlates with improved outcome upon consolidation chemotherapy with high-dose cytarabine-based regimens
scholarly article by George Z Rassidakis et al published 19 October 2018 in Blood Cancer Journal
MER1, a novel organic arsenic derivative, has potent PML-RARalpha-independent cytotoxic activity against leukemia cells
artículo científico publicado en 2009
MLL-Rearranged Acute Lymphoblastic Leukemias Activate BCL-2 through H3K79 Methylation and Are Sensitive to the BCL-2-Specific Antagonist ABT-199.
artículo científico publicado en 2015
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/ progenitor cells
artículo científico publicado en 2016
MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy
artículo científico publicado en 2013
MYC protein expression is an important prognostic factor in acute myeloid leukemia
artículo científico publicado en 2018
Malignancies occurring during therapy with tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) and other hematologic malignancies
artículo científico publicado en 2011
Malignancy-associated hemophagocytic lymphohistiocytosis in adults: Relation to hemophagocytosis, characteristics, and outcomes
artículo científico publicado en 2016
Management of Venetoclax-Posaconazole Interaction in Acute Myeloid Leukemia Patients: Evaluation of Dose Adjustments
artículo científico
Management of chronic myeloid leukemia during pregnancy among patients treated with a tyrosine kinase inhibitor: a single-Center experience
scientific article published on 07 December 2020
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
artículo científico publicado en 2013
Management of imatinib-resistant patients with chronic myeloid leukemia
artículo científico publicado en 2013
Management of patients with newly diagnosed chronic myeloid leukemia: opportunities and challenges.
artículo científico publicado en 2007
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience
artículo científico publicado en 2004
Managing iron overload in patients with myelodysplastic syndromes with oral deferasirox therapy
artículo científico publicado en 2009
Market spiral pricing of cancer drugs.
artículo científico publicado en 2013
Masking of neutropenic patients on transport from hospital rooms is associated with a decrease in nosocomial aspergillosis during construction.
artículo científico publicado en 2002
Mast cell leukemia (MCL): Clinico-pathologic and molecular features and survival outcome
artículo científico publicado en 2017
Mature T-cell leukemias
artículo científico publicado en 2005
Measuring the symptom burden associated with the treatment of chronic myeloid leukemia
artículo científico publicado en 2013
Mechanisms of antileukemic activity of the novel Bcl-2 homology domain-3 mimetic GX15-070 (obatoclax).
artículo científico publicado en 2008
Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment
artículo científico publicado en 2012
Mechanisms of constitutive activation of Janus kinase 2-V617F revealed at the atomic level through molecular dynamics simulations
artículo científico publicado en 2009
Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia
artículo científico publicado en 2009
Meir Wetzler, MD.
artículo científico publicado en 2015
Mesenchymal Stem Cells Differentiate into Osteoblasts in the Presence of AML Cells through Up-regulation of RUNX2 and Induce Chemo-resistance
article by V. Lokesh Battula et al published June 2015 in Clinical Lymphoma, Myeloma & Leukemia
MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia
artículo científico publicado en 2008
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
artículo científico publicado en 2011
Minimal residual disease assessed by multi-parameter flow cytometry is highly prognostic in adult patients with acute lymphoblastic leukaemia
artículo científico publicado en 2015
Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia
artículo científico publicado en 2017
Mitoxantrone and prolonged infusion gemcitabine as salvage therapy in patients with acute myelogenous leukemia
artículo científico publicado en 2003
Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemias
artículo científico publicado en 2010
Modern treatment programs for adults with acute lymphoblastic leukemia
artículo científico publicado en 2007
Modest activity of pomalidomide in patients with myelofibrosis and significant anemia
artículo científico publicado en 2013
Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon α-2a
artículo científico publicado en 2013
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations
artículo científico publicado en 2008
Molecular characterization of de novo Philadelphia chromosome-positive acute myeloid leukemia
artículo científico publicado en 2012
Molecular differences between small and large cells in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
Molecular monitoring in chronic myeloid leukemia: response to tyrosine kinase inhibitors and prognostic implications
artículo científico publicado en 2008
Molecular resistance: an early indicator for treatment change?
artículo científico
Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
artículo científico publicado en 2005
Monitoring molecular response in chronic myeloid leukemia
⬇️
artículo científico publicado el 19 de octubre de 2010
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods
artículo científico publicado en 2007
Monoclonal antibody therapy for hairy cell leukemia
artículo científico publicado en 2006
Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia
artículo científico publicado en 2009
Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia
artículo científico publicado en 2012
More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia.
artículo científico publicado en 2017
Multicenter study of decitabine administered daily for 5 days every 4 weeks to adults with myelodysplastic syndromes: the alternative dosing for outpatient treatment (ADOPT) trial
artículo científico publicado en 2009
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2012
Multiple recurrent extra-medullary relapses of high-grade diffuse large B-cell lymphoma presenting in acute leukemic phase
artículo científico publicado en 2013
Multivariable model for time to first treatment in patients with chronic lymphocytic leukemia
artículo científico publicado en 2011
Multivariate and subgroup analyses of a randomized, multinational, phase 3 trial of decitabine vs treatment choice of supportive care or cytarabine in older patients with newly diagnosed acute myeloid leukemia and poor- or intermediate-risk cytogene
artículo científico publicado en 2014
Mutant BCR-ABL clones in chronic myeloid leukemia
artículo científico publicado en 2011
Mutated NPM1 in patients with acute myeloid leukemia in remission and relapse
artículo científico publicado en 2013
Mutation in the ATP-binding pocket of the ABL kinase domain in an STI571-resistant BCR/ABL-positive cell line
artículo científico publicado en 2002
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias
artículo científico publicado en 2008
Mutational landscape of myelodysplastic/myeloproliferative neoplasm-unclassifiable
artículo científico publicado en 2018
Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
artículo científico publicado en 2014
Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
artículo científico publicado en 2006
Myelodysplastic syndromes: the complexity of stem-cell diseases
artículo científico publicado en 2007
Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm.
artículo científico publicado en 2017
Myeloid sarcoma is associated with superior event-free survival and overall survival compared with acute myeloid leukemia
artículo científico publicado en 2008
Myeloid/lymphoid neoplasms with FGFR1 rearrangement
artículo científico publicado en 2017
Myelopathy following intrathecal chemotherapy in adults: a single institution experience
artículo científico publicado en 2015
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2002
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia
artículo científico publicado en 2003
N-(4-Hydroxylphenyl)retinamide (fenretinide, 4-HPR), a retinoid compound with antileukemic and proapoptotic activity in acute lymphoblastic leukemia (ALL).
artículo científico publicado en 2003
NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017.
artículo científico publicado en 2017
NCCN Guidelines Insights: Chronic Myeloid Leukemia, Version 1.2017.
artículo científico publicado en 2016
NPM1 mutant variant allele frequency correlates with leukemia burden but does not provide prognostic information in NPM1-mutated acute myeloid leukemia
artículo científico publicado en 2019
Natural History of Newly Diagnosed Myelodysplastic Syndrome with Isolated Inv(3)/t(3;3)
artículo científico publicado en 2020
Natural history of chronic myelomonocytic leukemia treated with hypomethylating agents
artículo científico publicado en 2017
Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia
artículo científico publicado en 2007
Neutrophilic-chronic myeloid leukemia
Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course
artículo científico publicado en 2002
New Series: SOHO 'State of the Art Updates and Next Questions'.
artículo científico publicado en 2017
New Tool for Monitoring Molecular Response in Patients With Chronic Myeloid Leukemia
artículo científico publicado en 2017
New agents in acute myeloid leukemia and other myeloid disorders
artículo científico publicado en 2004
New agents in the treatment of acute lymphocytic leukaemia
artículo científico publicado en 2002
New approaches in the treatment of myelofibrosis
artículo científico publicado en 2005
New approaches to the management of Philadelphia-chromosome-positive acute lymphocytic leukemia
artículo científico publicado en 2007
New developments in the treatment of chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia
scientific article published on February 2011
New insights into the pathophysiology and therapy of adult acute lymphoblastic leukemia
artículo científico
New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
artículo científico publicado en 2006
New nucleoside analogues in clinical development
artículo científico publicado el 1 de enero de 2002
New strategies in chronic myeloid leukemia
artículo científico publicado en 2006
New targeted approaches in chronic myeloid leukemia
artículo científico publicado en 2005
New targeted therapies for chronic myelogenous leukemia: opportunities to overcome imatinib resistance
artículo científico publicado en 2007
Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring
artículo científico publicado en 2013
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
artículo científico publicado en 2007
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
artículo científico publicado en 2007
Nilotinib as front-line treatment for patients with chronic myeloid leukemia in early chronic phase
artículo científico publicado en 2009
Nilotinib for the treatment of Philadelphia-chromosome-positive chronic myeloid leukemia
⬇️
artículo científico publicado el 13 de noviembre de 2010
Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review
⬇️
artículo científico publicado el 15 de junio de 2010
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL
artículo científico publicado en 2006
Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study
artículo científico publicado en 2015
Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase
scientific article published on 15 March 2013
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
artículo científico publicado en 2010
Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia
article
Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
artículo científico publicado en 2010
Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial
artículo científico publicado en 2011
Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era.
artículo científico publicado en 2009
Novel Therapies for Older Adults With Acute Lymphoblastic Leukemia
artículo científico publicado en 2018
Novel approaches in the treatment of systemic mastocytosis
artículo científico publicado en 2006
Novel monoclonal antibody-based treatment strategies in adults with acute lymphoblastic leukemia.
artículo científico publicado en 2019
Novel therapies for myelodysplastic syndromes
artículo científico publicado en 2004
Novel therapies for patients with chronic myeloid leukemia
artículo científico publicado en 2004
Novel therapies for relapsed acute lymphoblastic leukemia
artículo científico publicado en 2009
Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity
scientific article published on 01 July 2007
Novel tyrosine kinase inhibitors in chronic myelogenous leukemia
artículo científico publicado en 2006
Omacetaxine mepesuccinate (synribo) - newly launched in chronic myeloid leukemia
artículo científico publicado en 2013
Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors
artículo científico publicado en 2013
Oncogenic signals as treatment targets in classic myeloproliferative neoplasms
artículo científico publicado en 2009
Optimal first-line treatment of chronic myeloid leukemia. How to use imatinib and what role for newer drugs?
artículo científico publicado en 2007
Optimizing the use of the hyperCVAD regimen: Clinical vignettes and practical management
scientific article published on 03 December 2019
Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2010
Optimizing treatment for elderly patients with acute promyelocytic leukemia: is it time to replace chemotherapy with all-trans retinoic acid and arsenic trioxide?
artículo científico publicado en 2006
Optimizing treatment with Bcr-Abl tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia: focus on dosing schedules
artículo científico publicado en 2008
Oral cedazuridine/decitabine: a phase 2, pharmacokinetic/pharmacodynamic, randomized, crossover study in MDS and CMML
scientific article published on 13 April 2020
Oral clofarabine in the treatment of patients with higher-risk myelodysplastic syndrome
artículo científico publicado en 2010
Oral sapacitabine for the treatment of acute myeloid leukaemia in elderly patients: a randomised phase 2 study
artículo científico publicado en 2012
Other malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma
scientific article published on 29 December 2008
Outcome after failure of second generation tyrosine kinase inhibitors treatment as first-line therapy for patients with chronic myeloid leukemia
artículo científico publicado en 2013
Outcome of Patients With Therapy-Related Acute Myeloid Leukemia With or Without a History of Myelodysplasia
artículo científico publicado en 2016
Outcome of adults with acute lymphocytic leukemia after second salvage therapy
artículo científico publicado en 2008
Outcome of adults with acute lymphocytic leukemia in second or subsequent complete remission
artículo científico publicado en 2010
Outcome of adults with relapsed/refractory T-cell acute lymphoblastic leukemia or lymphoblastic lymphoma
artículo científico publicado en 2020
Outcome of patients with FLT3-mutated acute myeloid leukemia in first relapse
artículo científico publicado en 2009
Outcome of patients with acute myelogenous leukemia after second salvage therapy
artículo científico publicado en 2005
Outcome of patients with chronic myeloid leukemia with multiple ABL1 kinase domain mutations receiving tyrosine kinase inhibitor therapy
artículo científico publicado en 2011
Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium
artículo científico publicado en 2014
Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy
artículo científico publicado en 2010
Outcome of patients with relapsed/refractory acute lymphoblastic leukemia after blinatumomab failure: No change in the level of CD19 expression
artículo científico publicado en 2017
Outcome of therapy-related acute promyelocytic leukemia with or without arsenic trioxide as a component of frontline therapy
artículo científico publicado en 2010
Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure
artículo científico publicado en 2011
Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma
artículo científico publicado en 2004
Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation
artículo científico publicado en 2013
Outcomes of Patients With Relapsed Core Binding Factor-Positive Acute Myeloid Leukemia
artículo científico publicado en 2017
Outcomes of acute myeloid leukemia with myelodysplasia related changes depend on diagnostic criteria and therapy
scientific article published on 28 February 2020
Outcomes of adults with relapsed or refractory Burkitt and high-grade B-cell leukemia/lymphoma
artículo científico publicado en 2017
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib
artículo científico publicado en 2015
Outcomes of patients with chronic phase chronic myeloid leukemia (CML-CP) after discontinuation of frontline ponatinib therapy
artículo científico publicado en 2019
Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents
scientific article published on 22 December 2015
Outcomes of patients with myelodysplatic syndrome and chronic myelomonocytic leukemia post clofarabine failure
artículo científico publicado en 2014
Outcomes with lower intensity therapy in TP53-mutated acute myeloid leukemia
artículo científico publicado en 2018
Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
scientific article published on 08 October 2020
Outpatient consolidation treatment with clofarabine in a phase 2 study of older adult patients with previously untreated acute myelogenous leukemia
artículo científico publicado en 2011
Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation
artículo científico publicado en 2017
P53 protein overexpression in de novo acute myeloid leukemia patients with normal diploid karyotype correlates with FLT3 internal tandem duplication and worse relapse-free survival
scientific article published on 23 September 2018
PEG-IFN-alpha-2b therapy in BCR-ABL-negative myeloproliferative disorders: final result of a phase 2 study
artículo científico publicado en 2007
Patient Characteristics and Outcomes in Adolescents and Young Adults (AYA) With Acute Myeloid Leukemia (AML).
artículo científico publicado en 2016
Patient adherence to tyrosine kinase inhibitor therapy in chronic myeloid leukemia
artículo científico publicado en 2012
Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms
artículo científico publicado en 2017
Patient-driven discontinuation of tyrosine kinase inhibitors: single institution experience
artículo científico publicado en 2013
Patient-reported outcomes from a phase 3 randomized controlled trial of inotuzumab ozogamicin versus standard therapy for relapsed/refractory acute lymphoblastic leukemia.
artículo científico publicado en 2018
Patients with polycythemia vera and essential thrombocythemia with prior malignancy do not have significantly worse outcome
artículo científico publicado en 2013
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis
artículo científico publicado en 2017
Patterns of molecular response to and relapse after combination of sorafenib, idarubicin, and cytarabine in patients with FLT3 mutant acute myeloid leukemia
artículo científico publicado en 2011
Pegylated interferon alfa-2a in patients with essential thrombocythaemia or polycythaemia vera: a post-hoc, median 83 month follow-up of an open-label, phase 2 trial
artículo científico publicado en 2017
Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera
artículo científico publicado en 2009
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disorders
artículo científico publicado en 2006
Percentage of Philadelphia chromosome (Ph)-negative and Ph-positive cells found after autologous transplantation for chronic myelogenous leukemia depends on percentage of diploid cells induced by conventional-dose chemotherapy before collection of a
artículo científico publicado en 1995
Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy
artículo científico publicado en 2016
Persistence of cytogenetic abnormalities at complete remission after induction in patients with acute myeloid leukemia: prognostic significance and the potential role of allogeneic stem-cell transplantation
artículo científico publicado en 2011
Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia
artículo científico publicado en 2016
Persistent mutations in remission can predict relapse in patients with acute myeloid leukemia
scholarly article by Chi Young Ok et al published February 2019 in Haematologica
Ph-like acute lymphoblastic leukemia: a high-risk subtype in adults
artículo científico publicado en 2016
Pharmacokinetic evaluation of decitabine for the treatment of leukemia
artículo científico publicado en 2011
Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias.
artículo científico publicado en 2003
Pharmacokinetics of posaconazole prophylaxis of patients with acute myeloid leukemia
artículo científico publicado en 2015
Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction
artículo científico publicado en 2009
Phase 1 Study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients
artículo científico publicado en 2020
Phase 1 dose escalation multicenter trial of pracinostat alone and in combination with azacitidine in patients with advanced hematologic malignancies
artículo científico publicado en 2017
Phase 1 dose escalation trial of ilorasertib, a dual Aurora/VEGF receptor kinase inhibitor, in patients with hematologic malignancies
artículo científico publicado en 2015
Phase 1 dose-finding study of rebastinib (DCC-2036) in patients with relapsed chronic myeloid leukemia and acute myeloid leukemia
artículo científico publicado en 2016
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemia
artículo científico publicado en 2009
Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies
artículo científico publicado en 2005
Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance
artículo científico publicado en 2010
Phase 1 study of an anti-CD33 immunotoxin, humanized monoclonal antibody M195 conjugated to recombinant gelonin (HUM-195/rGEL), in patients with advanced myeloid malignancies
artículo científico publicado en 2012
Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies
artículo científico publicado en 2003
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
artículo científico publicado en 2008
Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure
artículo científico publicado en 2007
Phase 1/2 study of DFP-10917 administered by continuous intravenous infusion in patients with recurrent or refractory acute myeloid leukemia
scientific article published on 22 January 2019
Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia
artículo científico publicado en 2006
Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia
artículo científico publicado en 2011
Phase 2 Study of Hyper-CMAD with Liposomal Vincristine for Patients with Newly Diagnosed Acute Lymphoblastic Leukemia
artículo científico publicado en 2020
Phase 2 and pharmacodynamic study of oral forodesine in patients with advanced, fludarabine-treated chronic lymphocytic leukemia
artículo científico publicado en 2010
Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia
artículo científico publicado en 2003
Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia
artículo científico publicado en 2011
Phase 2 study of CEP-701, an orally available JAK2 inhibitor, in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
artículo científico publicado en 2009
Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
artículo científico publicado en 2013
Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia
artículo científico publicado en 2011
Phase 2 study of low-dose clofarabine plus cytarabine for patients with higher-risk myelodysplastic syndrome who have relapsed or are refractory to hypomethylating agents
artículo científico publicado en 2016
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
artículo científico publicado en 2010
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
artículo científico publicado en 2012
Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
artículo científico publicado en 2012
Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.
artículo científico publicado en 2018
Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma
artículo científico publicado en 2008
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher-risk myelodysplastic syndromes
artículo científico publicado en 2017
Phase 2b study of 2 dosing regimens of quizartinib monotherapy in -ITD-mutated, relapsed or refractory AML
Phase 3 results for vosaroxin/cytarabine in the subset of patients ≥60 years old with refractory/early relapsed acute myeloid leukemia
scholarly article by Farhad Ravandi et al published November 2018 in Haematologica
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up
artículo científico publicado en 2009
Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2013
Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia
artículo científico publicado en 2003
Phase I and pharmacokinetic study of DX-8951f (exatecan mesylate), a hexacyclic camptothecin, on a daily-times-five schedule in patients with advanced leukemia
artículo científico publicado en 2002
Phase I and pharmacokinetic study of a low-clearance, unilamellar liposomal formulation of lurtotecan, a topoisomerase 1 inhibitor, in patients with advanced leukemia
artículo científico publicado en 2004
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome
artículo científico publicado en 2009
Phase I clinical and pharmacology study of clofarabine in patients with solid and hematologic cancers.
artículo científico publicado en 2003
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
artículo científico publicado en 2013
Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor
artículo científico publicado en 2013
Phase I evaluation of a 40-kDa branched-chain long-acting pegylated IFN-alpha-2a with and without cytarabine in patients with chronic myelogenous leukemia
artículo científico publicado en 2005
Phase I studies of AZD1208, a proviral integration Moloney virus kinase inhibitor in solid and haematological cancers.
artículo científico publicado en 2018
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
artículo científico publicado en 2013
Phase I study of BMS-214662, a farnesyl transferase inhibitor in patients with acute leukemias and high-risk myelodysplastic syndromes
artículo científico publicado en 2005
Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in patients with refractory hematologic malignancies
artículo científico publicado en 2015
Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies
artículo científico publicado en 2015
Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome
artículo científico publicado en 2008
Phase I study of bortezomib in refractory or relapsed acute leukemias
artículo científico publicado en 2004
Phase I study of cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, combined with cytarabine in patients with refractory leukemia
artículo científico publicado en 2005
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia
artículo científico publicado en 2016
Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia
artículo científico publicado en 2011
Phase I study of oral topotecan in hematological malignancies
⬇️
artículo científico publicado el 15 de septiembre de 2003
Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status
artículo científico publicado en 2013
Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation
scientific article published on 14 September 2018
Phase I study of sorafenib in patients with refractory or relapsed acute leukemias
artículo científico publicado en 2010
Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells
artículo científico publicado en 2016
Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome
artículo científico publicado en 2013
Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome
artículo científico publicado en 2012
Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia
artículo científico publicado en 2008
Phase I/II Study of Dasatinib in Combination with Decitabine in Patients with Accelerated or Blast Phase Chronic Myeloid Leukemia
artículo científico publicado en 2020
Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia
artículo científico publicado en 2010
Phase I/II study of low-dose azacytidine in patients with chronic myeloid leukemia who have minimal residual disease while receiving therapy with tyrosine kinase inhibitors.
artículo científico publicado en 2016
Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy.
artículo científico publicado en 2007
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia
artículo científico publicado en 2015
Phase I/II trial of nanomolecular liposomal annamycin in adult patients with relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2013
Phase I/II trial of the combination of midostaurin (PKC412) and 5-azacytidine for patients with acute myeloid leukemia and myelodysplastic syndrome
artículo científico publicado en 2015
Phase II Trial of MEK Inhibitor Binimetinib (MEK162) in RAS-mutant Acute Myeloid Leukemia
scientific article published on 20 December 2018
Phase II evaluation of IPI-926, an oral Hedgehog inhibitor, in patients with myelofibrosis
artículo científico publicado en 2015
Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome
artículo científico publicado en 2004
Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma
artículo científico publicado en 2004
Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases
artículo científico publicado en 2003
Phase II study of alemtuzumab in combination with pentostatin in patients with T-cell neoplasms
artículo científico publicado en 2009
Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors
artículo científico publicado en 2009
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis
artículo científico publicado en 2008
Phase II study of fludarabine, cytarabine (Ara-C), cyclophosphamide, cisplatin and GM-CSF (FACPGM) in patients with Richter's syndrome or refractory lymphoproliferative disorders
artículo científico publicado en 2002
Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis
artículo científico publicado en 2009
Phase II study of low-dose decitabine in combination with imatinib mesylate in patients with accelerated or myeloid blastic phase of chronic myelogenous leukemia.
artículo científico publicado en 2007
Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate
artículo científico publicado en 2005
Phase II study of methotrexate, vincristine, pegylated-asparaginase, and dexamethasone (MOpAD) in patients with relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2014
Phase II study of obatoclax mesylate (GX15-070), a small-molecule BCL-2 family antagonist, for patients with myelofibrosis
artículo científico publicado en 2010
Phase II study of pomalidomide in combination with prednisone in patients with myelofibrosis and significant anemia
artículo científico publicado en 2014
Phase II study of sunitinib in patients with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis
artículo científico publicado en 2010
Phase II study of the histone deacetylase inhibitor panobinostat (LBH589) in patients with low or intermediate-1 risk myelodysplastic syndrome
artículo científico publicado en 2011
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with refractory leukemia
artículo científico publicado en 2002
Phase II study of troxacitabine, a novel dioxolane nucleoside analog, in patients with untreated or imatinib mesylate-resistant chronic myelogenous leukemia in blastic phase
artículo científico publicado en 2003
Phase II trial of CPX-351 in patients with acute myeloid leukemia at high risk for induction mortality
artículo científico publicado en 2020
Phase II trial of homoharringtonine with imatinib in chronic, accelerated, and blast phase chronic myeloid leukemia
artículo científico publicado en 2017
Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia
artículo científico publicado en 2014
Phase II trial of ponatinib in patients with chronic myeloid leukemia resistant to one previous tyrosine kinase inhibitor
artículo científico publicado en 2015
Phase II trial of vorinostat with idarubicin and cytarabine for patients with newly diagnosed acute myelogenous leukemia or myelodysplastic syndrome
artículo científico publicado en 2012
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose c
Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimizati
artículo científico publicado en 2009
Phase Ib Study of Glasdegib, A Hedgehog Pathway Inhibitor, in Combination With Standard Chemotherapy in Patients With AML or High-Risk MDS.
artículo científico publicado en 2018
Philadelphia chromosome-negative acute leukemia in patients with chronic myeloid leukemia
scientific article published on 28 July 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors
artículo científico publicado en 2019
Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives.
artículo científico publicado en 2018
Philadelphia chromosome-positive acute lymphoblastic leukemia- current concepts and future perspectives
artículo científico publicado en 2002
Philadelphia chromosome-positive leukemias: from basic mechanisms to molecular therapeutics
artículo científico publicado en 2003
Philadelphia-positive acute lymphoblastic leukemia: current treatment options
artículo científico
Phosphorylated CXCR4 is associated with poor survival in adults with B-acute lymphoblastic leukemia
artículo científico publicado en 2011
Phosphorylation levels of BCR-ABL, CrkL, AKT and STAT5 in imatinib-resistant chronic myeloid leukemia cells implicate alternative pathway usage as a survival strategy
artículo científico publicado en 2007
Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia
artículo científico publicado en 2002
Pilot study of bortezomib for patients with imatinib-refractory chronic myeloid leukemia in chronic or accelerated phase
artículo científico publicado en 2011
Pilot study of gemtuzumab ozogamicin, liposomal daunorubicin, cytarabine and cyclosporine regimen in patients with refractory acute myelogenous leukemia
artículo científico publicado en 2003
Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy
artículo científico publicado en 2006
Pilot study of pegylated interferon-alpha 2b in patients with essential thrombocythemia
artículo científico publicado en 2002
Plasma circulating-microRNA profiles are useful for assessing prognosis in patients with cytogenetically normal myelodysplastic syndromes
artículo científico publicado en 2014
Plasma inhibitory activity (PIA): a pharmacodynamic assay reveals insights into the basis for cytotoxic response to FLT3 inhibitors
artículo científico publicado en 2006
Plasma thrombopoietin compared with immunoglobulin heavy-chain mutation status as a predictor of survival in chronic lymphocytic leukemia.
artículo científico publicado en 2006
Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure
article
Ponatinib as first-line treatment for patients with chronic myeloid leukaemia in chronic phase: a phase 2 study
artículo científico publicado en 2015
Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial.
artículo científico publicado en 2018
Ponatinib in patients with refractory acute myeloid leukaemia: findings from a phase 1 study
artículo científico publicado en 2013
Ponatinib in refractory Philadelphia chromosome-positive leukemias
artículo científico publicado en 2012
Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial
artículo científico publicado en 2016
Poor outcomes associated with +der(22)t(9;22) and -9/9p in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia receiving chemotherapy plus a tyrosine kinase inhibitor
artículo científico publicado en 2016
Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase
artículo científico publicado en 2011
Post hoc analysis of the relationship between baseline white blood cell count and survival outcome in a randomized Phase III trial of decitabine in older patients with newly diagnosed acute myeloid leukemia
artículo científico publicado en 2015
Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors
scientific article published on 03 March 2020
Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response o
article
Potential curability of newly diagnosed acute promyelocytic leukemia without use of chemotherapy: the example of liposomal all-trans retinoic acid
artículo científico publicado en 2005
Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia
artículo científico publicado en 2013
Potential role of novel nucleoside analogs in the treatment of acute myeloid leukemia
artículo científico publicado en 2008
Potential role of sorafenib in the treatment of acute myeloid leukemia
artículo científico publicado en 2008
Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
artículo científico publicado en 2010
Practical issues surrounding the explosion of tyrosine kinase inhibitors for the management of chronic myeloid leukemia
artículo científico
Practical management of toxicities associated with tyrosine kinase inhibitors in chronic myeloid leukemia
artículo científico publicado en 2008
Preclinical and early clinical evaluation of the oral AKT inhibitor, MK-2206, for the treatment of acute myelogenous leukemia
scientific article published on 28 February 2014
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor
artículo científico publicado en 2010
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
artículo científico publicado en 2010
Precursor B-acute lymphoblastic leukemia occurring in patients with a history of prior malignancies: is it therapy-related?
artículo científico publicado en 2011
Predicting outcomes in patients with chronic myeloid leukemia at any time during tyrosine kinase inhibitor therapy
artículo científico publicado en 2014
Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system
artículo científico publicado en 2012
Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase
artículo científico publicado en 2017
Prediction model for mortality after intracranial hemorrhage in patients with leukemia
artículo científico publicado en 2011
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
artículo científico publicado en 2011
Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia
artículo científico publicado en 2003
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
artículo científico publicado en 2010
Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2010
Predictors of primary imatinib resistance in chronic myelogenous leukemia are distinct from those in secondary imatinib resistance
artículo científico publicado en 2009
Pregnancy among patients with chronic myeloid leukemia treated with imatinib
artículo científico publicado en 2006
Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study
artículo científico
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis resear
artículo científico publicado en 2007
Proceedings of the Third Annual Meeting of the Society of Hematologic Oncology
artículo científico publicado en 2016
Proceedings of the Third Global Workshop on Chronic Myeloid Leukemia
artículo científico publicado en 2010
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R
scientific article published on 26 September 2018
Prognostic factors and risk assessment in chronic myelomonocytic leukemia: validation study of the M.D. Anderson Prognostic Scoring System
artículo científico publicado en 2007
Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients
artículo científico publicado en 2002
Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients
artículo científico publicado en 2017
Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine
artículo científico publicado en 2012
Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody
artículo científico publicado en 2015
Prognostic impact and targeting of CRM1 in acute myeloid leukemia
artículo científico publicado en 2013
Prognostic impact of RAS mutations in patients with myelodysplastic syndrome
artículo científico publicado en 2013
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib
artículo científico publicado en 2011
Prognostic impact of persistent cytogenetic abnormalities at complete remission in adult patients with acute lymphoblastic leukemia
artículo científico publicado en 2016
Prognostic impact of pretreatment cytogenetics in adult Philadelphia chromosome-negative acute lymphoblastic leukemia in the era of minimal residual disease
artículo científico publicado en 2016
Prognostic implications and clinical characteristics associated with bone marrow fibrosis in patients with myelofibrosis
artículo científico publicado en 2013
Prognostic implications of chromosome 17 abnormalities in the context of monosomal karyotype in patients with acute myeloid leukemia and complex cytogenetics
artículo científico publicado en 2014
Prognostic implications of cytogenetics in adults with acute lymphoblastic leukemia treated with inotuzumab ozogamicin
artículo científico publicado en 2019
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemia
artículo científico publicado en 2013
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
artículo científico publicado en 2007
Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia
artículo científico publicado en 2008
Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors
artículo científico publicado en 2017
Prognostic significance of alterations in IDH enzyme isoforms in patients with AML treated with high-dose cytarabine and idarubicin
artículo científico publicado en 2011
Prognostic significance of baseline FLT3-ITD mutant allele level in acute myeloid leukemia treated with intensive chemotherapy with/without sorafenib
artículo científico publicado en 2019
Prognostic significance of cytogenetic clonal evolution in patients with chronic myelogenous leukemia on imatinib mesylate therapy
artículo científico publicado en 2003
Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia
artículo científico publicado en 2016
Prognostic significance of hyperdiploidy in adult acute myeloid leukemia
artículo científico publicado en 2018
Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B‐lymphoblastic leukemia in the era of tyrosine kinase inhibitors
⬇️
artículo científico publicado el 1 de septiembre de 2011
Prognostic significance of the Medical Research Council cytogenetic classification compared with the European LeukaemiaNet risk classification system in acute myeloid leukaemia
artículo científico publicado en 2015
Prognostic value of FLT3 mutations among different cytogenetic subgroups in acute myeloid leukemia
artículo científico publicado en 2010
Prognostic value of blasts in peripheral blood in myelofibrosis in the ruxolitinib era
artículo científico publicado en 2020
Progress in acute myeloid leukemia
artículo científico publicado en 2015
Progress in the treatment of acute myeloid leukemia
artículo científico publicado en 2007
Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome
artículo científico publicado en 2002
Pronounced hypoxia in models of murine and human leukemia: high efficacy of hypoxia-activated prodrug PR-104
artículo científico publicado en 2011
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
artículo científico publicado en 2008
Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
artículo científico publicado en 2006
Prospective, randomized study comparing quinupristin-dalfopristin with linezolid in the treatment of vancomycin-resistant Enterococcus faecium infections
artículo científico publicado en 2004
Proteasome enzymatic activities in plasma as risk stratification of patients with acute myeloid leukemia and advanced-stage myelodysplastic syndrome
artículo científico publicado en 2009
Proteomic-based prediction of clinical behavior in adult acute lymphoblastic leukemia
artículo científico publicado en 2006
Proteomics-based prediction of clinical response in acute myeloid leukemia
artículo científico publicado en 2009
Publisher Correction: Clonal evolution of acute myeloid leukemia revealed by high-throughput single-cell genomics
artículo científico publicado en 2020
Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia
artículo científico publicado en 2009
Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.
artículo científico publicado en 2003
Questions regarding frontline therapy of acute myeloid leukemia
artículo científico publicado en 2010
Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial.
artículo científico publicado en 2018
RIL, a LIM gene on 5q31, is silenced by methylation in cancer and sensitizes cancer cells to apoptosis.
artículo científico publicado en 2007
RUNX3 promoter hypermethylation is frequent in leukaemia cell lines and associated with acute myeloid leukaemia inv(16) subtype
artículo científico publicado en 2015
Randomized open-label phase II study of decitabine in patients with low- or intermediate-risk myelodysplastic syndromes
artículo científico publicado en 2013
Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.
artículo científico publicado en 2003
Rapid and reliable confirmation of acute promyelocytic leukemia by immunofluorescence staining with an antipromyelocytic leukemia antibody: the M. D. Anderson Cancer Center experience of 349 patients
artículo científico publicado en 2010
Rapid detection and quantitation of BRAF mutations in hairy cell leukemia using a sensitive pyrosequencing assay
artículo científico publicado en 2012
Recombinant interferon gamma1b immune enhancement in 20 patients with hematologic malignancies and systemic opportunistic infections treated with donor granulocyte transfusions.
artículo científico publicado en 2006
Recommendations for the Assessment and Management of Measurable Residual Disease in Adults With Acute Lymphoblastic Leukemia: A Consensus of North American Experts
artículo científico publicado en 2018
Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes
artículo científico publicado en 2008
Red blood cell-encapsulated L-asparaginase: potential therapy of patients with asparagine synthetase deficient acute myeloid leukemia
artículo científico publicado en 2013
Regulation of HIF-1α signaling and chemoresistance in acute lymphocytic leukemia under hypoxic conditions of the bone marrow microenvironment
artículo científico publicado en 2012
Relapse and death during first remission in acute myeloid leukemia
artículo científico publicado en 2008
Relapsed Refractory BRAF-Negative, IGHV4-34-Positive Variant of Hairy Cell Leukemia: A Distinct Entity?
artículo científico publicado en 2014
Relation between the duration of remission and hyperglycemia during induction chemotherapy for acute lymphocytic leukemia with a hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone/methotrexate-cytarabine regimen
artículo científico publicado en 2004
Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia
artículo científico publicado en 2013
Relative increase in leukemia-specific DNA in peripheral blood plasma from patients with acute myeloid leukemia and myelodysplasia
⬇️
artículo científico publicado el 23 de octubre de 2003
Relative survival in patients with chronic-phase chronic myeloid leukaemia in the tyrosine-kinase inhibitor era: analysis of patient data from six prospective clinical trials
artículo científico publicado en 2015
Relevance of the immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
artículo científico publicado en 2008
Reply to ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia
artículo científico publicado en 2017
Reply to Starting with a lower daily dose of dasatinib in patients with chronic myeloid leukemia in chronic phase: Less is more, or is it?
artículo científico publicado en 2018
Reply to price and value in cancer care
artículo científico publicado en 2015
Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes
artículo científico publicado en 2010
Residual DNA methylation at remission is prognostic in adult Philadelphia chromosome-negative acute lymphocytic leukemia
artículo científico publicado en 2008
Response kinetics and factors predicting survival in core-binding factor leukemia
artículo científico publicado en 2018
Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate
artículo científico publicado en 2002
Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-alpha
artículo científico publicado en 2003
Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse
artículo científico publicado en 2011
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib
artículo científico publicado en 2007
Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias
artículo científico publicado en 2004
Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia
artículo científico publicado en 2006
Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations
artículo científico publicado en 2010
Results of dasatinib therapy in patients with early chronic-phase chronic myeloid leukemia
artículo científico publicado en 2009
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia
artículo científico publicado en 2003
Results of imatinib mesylate therapy in chronic myelogenous leukaemia with variant Philadelphia chromosome
artículo científico publicado en 2004
Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders
artículo científico publicado en 2003
Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia
artículo científico publicado en 2013
Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia
artículo científico publicado en 2014
Results of second salvage therapy in 673 adults with acute myelogenous leukemia treated at a single institution since 2000.
artículo científico publicado en 2018
Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia
artículo científico publicado en 2008
Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase
artículo científico publicado en 2003
Resveratrol blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells
artículo científico publicado en 2003
Retrospect of hematological malignancies 2012.
artículo científico publicado en 2013
Retrospective analysis of prognostic factors associated with response and overall survival by baseline marrow blast percentage in patients with myelodysplastic syndromes treated with decitabine
artículo científico publicado en 2013
Retrospective comparison of clofarabine versus fludarabine in combination with high-dose cytarabine with or without granulocyte colony-stimulating factor as salvage therapies for acute myeloid leukemia
artículo científico publicado en 2012
Revised international prognostic scoring system for myelodysplastic syndromes
artículo científico publicado en 2012
Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial
artículo científico publicado en 2016
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy
scientific article published on 22 March 2016
Rituximab in relapsed or refractory hairy cell leukemia
artículo científico publicado en 2003
Role of inotuzumab ozogamicin in the treatment of relapsed/refractory acute lymphoblastic leukemia
artículo científico publicado en 2016
Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia
artículo científico publicado en 2010
Role of tyrosine kinase inhibitors in the management of Philadelphia chromosome-positive acute lymphoblastic leukemia
scientific article published on September 2011
Romiplostim monotherapy in thrombocytopenic patients with myelodysplastic syndromes: long-term safety and efficacy
artículo científico publicado en 2017
Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results
artículo científico publicado en 2017
Ruxolitinib for myelofibrosis--an update of its clinical effects
artículo científico publicado en 2013
Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial
artículo científico publicado en 2017
Ruxolitinib in combination with lenalidomide as therapy for patients with myelofibrosis
scientific article published on 18 June 2015
SL-401 and SL-501, targeted therapeutics directed at the interleukin-3 receptor, inhibit the growth of leukaemic cells and stem cells in advanced phase chronic myeloid leukaemia
artículo científico publicado en 2014
SOHO State of the Art Update and Next Questions: Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia.
artículo científico publicado en 2018
SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes
artículo científico publicado en 2003
Safety and Efficacy of Blinatumomab in Combination With a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-positive Leukemia
artículo científico publicado en 2017
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
artículo científico publicado en 2014
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
artículo científico publicado en 2014
Safety and clinical activity of 5-aza-2'-deoxycytidine (decitabine) with or without Hyper-CVAD in relapsed/refractory acute lymphocytic leukaemia
artículo científico publicado en 2014
Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis
artículo científico publicado en 2010
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
artículo científico publicado en 2011
Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thrombocytopenia
artículo científico publicado en 2009
Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase 1/2 study.
artículo científico publicado en 2018
Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily
artículo científico
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study
artículo científico publicado en 2018
Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study
artículo científico publicado en 2015
Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia
artículo científico publicado en 2014
Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini-Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Phase 2 Clinical Trial
artículo científico publicado en 2017
Salvage therapy using FLT3 inhibitors may improve long-term outcome of relapsed or refractory AML in patients with FLT3-ITD
artículo científico publicado en 2013
Sapacitabine for cancer
artículo científico publicado en 2012
Saving Medicare through patient-centered changes--the case of injectables
artículo científico publicado en 2013
Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes
artículo científico publicado en 2014
Second generation tyrosine kinase inhibitors for the treatment of chronic myelogenous leukemia. [An interview with Hagop Katarjian by H&O].
artículo científico publicado en 2008
Second-generation tyrosine kinase inhibitors: the future of frontline CML therapy
scientific article published on 09 February 2011
Second-line therapy and beyond resistance for the treatment of patients with chronic myeloid leukemia post imatinib failure
artículo científico publicado en 2009
Secondary Philadelphia chromosome acquired during therapy of acute leukemia and myelodysplastic syndrome
artículo científico publicado en 2018
Secondary myelodysplastic syndrome in a patient with Philadelphia-positive acute lymphoblastic leukemia after achieving a major molecular response with hyperCVAD plus imatinib mesylate
artículo científico publicado en 2008
Secondary solid tumors and lymphoma in patients with essential thrombocythemia and polycythemia vera - single center experience
artículo científico publicado en 2015
Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia
artículo científico publicado en 2013
Sequential azacitidine and lenalidomide in patients with high-risk myelodysplastic syndromes and acute myeloid leukaemia: a single-arm, phase 1/2 study
scientific article published on 22 December 2014
Severe periorbital edema secondary to STI571 (Gleevec).
artículo científico publicado en 2002
Significance of FAB subclassification of "acute myeloid leukemia, NOS" in the 2008 WHO classification: analysis of 5848 newly diagnosed patients
artículo científico publicado en 2013
Significance of cytogenetic abnormalities in patients with polycythemia vera
artículo científico publicado en 2013
Significance of deeper molecular responses in patients with chronic myeloid leukemia in early chronic phase treated with tyrosine kinase inhibitors
artículo científico publicado en 2013
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response
artículo científico publicado en 2009
Significance of myelofibrosis in early chronic-phase, chronic myelogenous leukemia on imatinib mesylate therapy
artículo científico publicado en 2005
Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission
artículo científico publicado en 2017
Significance of suboptimal response to imatinib, as defined by the European LeukemiaNet, in the long-term outcome of patients with early chronic myeloid leukemia in chronic phase
artículo científico publicado en 2009
Significance of thrombocytopenia in myelodysplastic syndromes: associations and prognostic implications
artículo científico publicado en 2011
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis
artículo científico publicado en 2017
Significant association between polymorphism of the erythropoietin gene promoter and myelodysplastic syndrome
artículo científico publicado en 2010
Similar outcome of patients with chronic myeloid leukemia treated with imatinib in or out of clinical trials
artículo científico publicado en 2013
Simultaneous Modeling of Biomarker and Toxicity Response Predicted Optimal Regimen of Guadecitabine (SGI-110) in Myeloid Malignancies
artículo científico publicado en 2017
Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia
artículo científico publicado en 2002
Single agent thalidomide in patients with relapsed or refractory acute myeloid leukaemia
artículo científico publicado en 2003
Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia
artículo científico publicado en 2004
Single-agent liposomal all-trans retinoic acid can cure some patients with untreated acute promyelocytic leukemia: an update of The University of Texas M. D. Anderson Cancer Center Series.
artículo científico publicado en 2006
Single-agent liposomal all-trans-retinoic Acid as initial therapy for acute promyelocytic leukemia: 13-year follow-up data
artículo científico publicado en 2013
Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells
artículo científico publicado en 2015
Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes
artículo científico publicado en 2004
Sorafenib Combined with 5-azacytidine in Older Patients with Untreated FLT3-ITD Mutated Acute Myeloid Leukemia
scientific article published on 31 August 2018
Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia
scientific article published on 16 July 2019
Splenectomy in patients with myeloproliferative neoplasms: efficacy, complications and impact on survival and transformation
artículo científico publicado en 2013
Stage I of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
artículo científico publicado en 2013
Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal
artículo científico publicado en 2006
Standard management of patients with chronic myeloid leukemia
artículo científico publicado en 2009
Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.
artículo científico publicado en 2010
Strategies that delay or prevent the timely availability of affordable generic drugs in the United States
scientific article published on 27 January 2016
Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations
artículo científico publicado en 2009
Subcutaneous omacetaxine mepesuccinate in patients with chronic-phase chronic myeloid leukemia previously treated with 2 or more tyrosine kinase inhibitors including imatinib
artículo científico publicado en 2013
Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromes
⬇️
artículo científico publicado el 13 de octubre de 2010
Suboptimal response to or failure of imatinib treatment for chronic myeloid leukemia: what is the optimal strategy?
scientific article published on February 2009
Suboptimal responses in chronic myeloid leukemia: implications and management strategies
artículo científico publicado en 2011
Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature
scientific article published on August 2009
Successful lenalidomide treatment in high risk myelodysplastic syndrome with germline DDX41 mutation
scientific article published on 29 August 2019
Sudden blastic transformation in patients with chronic myeloid leukemia treated with imatinib mesylate
artículo científico publicado en 2005
Sudden onset of the blastic phase of chronic myelogenous leukemia: patterns and implications
artículo científico publicado en 2003
Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities
artículo científico publicado en 2009
Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience
artículo científico publicado en 2007
Survival advantage with imatinib mesylate therapy in chronic-phase chronic myelogenous ;eukemia (CML-CP) after IFN-alpha failure and in late CML-CP, comparison with historical controls
artículo científico publicado en 2004
Survival benefit with imatinib mesylate therapy in patients with accelerated-phase chronic myelogenous leukemia--comparison with historic experience
artículo científico publicado en 2005
Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia
artículo científico publicado en 2009
Survival outcomes for clonal evolution in chronic myeloid leukemia patients on second generation tyrosine kinase inhibitor therapy
artículo científico publicado en 2010
Survivin is highly expressed in CD34(+)38(-) leukemic stem/progenitor cells and predicts poor clinical outcomes in AML
artículo científico publicado en 2012
Survivorship in AML - a landmark analysis on the outcomes of acute myelogenous leukemia patients after maintaining complete remission for at least 3 years
artículo científico publicado en 2020
Sustained complete molecular response after imatinib discontinuation in a patient with chronic myeloid leukemia not previously exposed to interferon alpha
artículo científico publicado en 2008
Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials
artículo científico publicado en 2009
Synergistic effects of p53 activation via MDM2 inhibition in combination with inhibition of Bcl-2 or Bcr-Abl in CD34+ proliferating and quiescent chronic myeloid leukemia blast crisis cells
artículo científico publicado en 2015
Synthetic tumor-specific breakpoint peptide vaccine in patients with chronic myeloid leukemia and minimal residual disease: a phase 2 trial
artículo científico publicado en 2009
T-cell prolymphocytic leukemia: a single-institution experience
scientific article published on 01 November 2005
TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients
artículo científico publicado en 2014
TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases
artículo científico publicado en 2015
TP53 mutation does not confer a poor outcome in adult patients with acute lymphoblastic leukemia who are treated with frontline hyper-CVAD-based regimens
artículo científico publicado en 2017
TP53 mutations in newly diagnosed acute myeloid leukemia: Clinicomolecular characteristics, response to therapy, and outcomes
artículo científico publicado en 2016
TP53 overexpression is an independent adverse prognostic factor in de novo myelodysplastic syndromes with fibrosis
artículo científico publicado en 2015
Tamibarotene in patients with acute promyelocytic leukaemia relapsing after treatment with all-trans retinoic acid and arsenic trioxide
artículo científico publicado en 2015
Targeted multigene deep sequencing of Bruton tyrosine kinase inhibitor-resistant chronic lymphocytic leukemia with disease progression and Richter transformation
artículo científico publicado en 2018
Targeted therapies in hematology and their impact on patient care: chronic and acute myeloid leukemia
artículo científico publicado en 2013
Targeted therapy in chronic myeloid leukemia
artículo científico publicado en 2008
Targeted therapy: Generic imatinib - impact on frontline and salvage therapy for CML
artículo científico publicado en 2016
Targeting ABL and SRC kinases in chronic myeloid leukemia: experience with dasatinib
artículo científico publicado en 2006
Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells
artículo científico publicado en 2022
Targeting DNA methylation
scientific article published on 09 June 2009
Targeting IL11 Receptor in Leukemia and Lymphoma: A Functional Ligand-Directed Study and Hematopathology Analysis of Patient-Derived Specimens
artículo científico publicado en 2015
Targeting connective tissue growth factor (CTGF) in acute lymphoblastic leukemia preclinical models: anti-CTGF monoclonal antibody attenuates leukemia growth
artículo científico publicado en 2013
Targeting neuropilin-1 in human leukemia and lymphoma
artículo científico publicado en 2011
Targeting of mTORC1/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment
artículo científico publicado en 2012
Targeting the kinase activity of the BCR-ABL fusion protein in patients with chronic myeloid leukemia
artículo científico publicado en 2005
Telomerase activity is not a prognostic factor in chronic lymphocytic leukemia
artículo científico publicado en 2004
Telomere dysfunction drives aberrant hematopoietic differentiation and myelodysplastic syndrome
artículo científico publicado en 2015
Ten-year follow-up after intense chemoimmunotherapy with Rituximab-HyperCVAD alternating with Rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
artículo científico publicado en 2010
Thalidomide therapy for myelofibrosis with myeloid metaplasia
scientific article published on 01 May 2006
The "American (cancer) patients first" plan to reduce drug prices-A critical assessment
scientific article published on 09 October 2018
The Addition of All-Trans Retinoic Acid to Chemotherapy May Not Improve the Outcome of Patient with NPM1 Mutated Acute Myeloid Leukemia
artículo científico publicado en 2013
The BiTE (Bispecific T-Cell engager) platform: development and future potential of a targeted immuno-oncology therapy across Tumor Types
scientific article published on 13 May 2020
The Hippocratic Oath, the US Health Care System, and the Affordable Care Act in 2015.
artículo científico publicado en 2015
The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation
artículo científico publicado en 2008
The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis
artículo científico publicado en 2009
The Opioid Epidemic in the United States-Overview, Origins, and Potential Solutions
artículo científico publicado en 2018
The Search for Better Prognostic Models in Myelodysplastic Syndromes
⬇️
artículo científico publicado el 1 de marzo de 2011
The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia
artículo científico publicado en 2014
The Urgent Need for Clinical Research Reform to Permit Faster, Less Expensive Access to New Therapies for Lethal Diseases.
artículo científico publicado en 2015
The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab
artículo científico publicado en 2017
The achievement of a 3-month complete cytogenetic response to second-generation tyrosine kinase inhibitors predicts survival in patients with chronic phase chronic myeloid leukemia after imatinib failure
artículo científico publicado en 2013
The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors
artículo científico publicado en 2011
The biology and therapy of adult acute lymphoblastic leukemia
⬇️
artículo científico publicado el 1 de octubre de 2003
The biology of chronic myelogenous leukemia: implications for imatinib therapy
artículo científico publicado en 2007
The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease
artículo científico publicado en 2002
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
artículo científico publicado en 2013
The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia
artículo científico publicado en 2013
The clinical significance of achieving different levels of cytogenetic response in patients with chronic phase chronic myeloid leukemia after failure to front-line therapy: is complete cytogenetic response the only desirable endpoint?
artículo científico publicado en 2011
The degree of bone marrow fibrosis in chronic myelogenous leukemia is not a prognostic factor with imatinib mesylate therapy
artículo científico publicado en 2005
The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
artículo científico
The distribution of T-cell subsets and the expression of immune checkpoint receptors and ligands in patients with newly diagnosed and relapsed acute myeloid leukemia
artículo científico publicado en 2018
The early achievement of measurable residual disease negativity in the treatment of adults with Philadelphia-negative B-cell acute lymphoblastic leukemia is a strong predictor for survival
scientific article published on 19 November 2019
The effect of calcium channel blockers on the outcome of acute myeloid leukemia
artículo científico publicado en 2014
The effect of decitabine dose modification and myelosuppression on response and survival in patients with myelodysplastic syndromes
artículo científico publicado en 2014
The effect of interleukin 11 on thrombocytopenia associated with tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia
artículo científico publicado en 2008
The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation
artículo científico publicado en 2014
The effects of imatinib on pregnancy outcome
artículo científico publicado en 2008
The efficacy of current prognostic models in predicting outcome of patients with myelodysplastic syndromes at the time of hypomethylating agent failure
artículo científico publicado en 2016
The emerging role of immune checkpoint based approaches in AML and MDS.
artículo científico publicado en 2017
The evolution of arsenic in the treatment of acute promyelocytic leukemia and other myeloid neoplasms: Moving toward an effective oral, outpatient therapy
artículo científico publicado en 2015
The financial burden and distress of patients with cancer: Understanding and stepping-up action on the financial toxicity of cancer treatment.
artículo científico publicado en 2018
The great imitator: systemic nocardiosis mimicking Richter's transformation in relapsed chronic lymphocytic leukemia
artículo científico publicado en 2010
The heterogeneous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?
artículo científico publicado en 2009
The impact of anemia on overall survival in patients with myelofibrosis treated with ruxolitinib in the COMFORT studies
artículo científico publicado en 2016
The importance of greater speed in drug development for advanced malignancies.
artículo científico publicado en 2018
The incidence and impact of thrombocytopenia in myelodysplastic syndromes
artículo científico publicado en 2007
The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms
artículo científico publicado en 2008
The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy
artículo científico publicado en 2007
The organic arsenic derivative GMZ27 induces PML-RARα-independent apoptosis in myeloid leukemia cells
artículo científico publicado en 2012
The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
artículo científico publicado en 2011
The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells
artículo científico publicado en 2007
The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes
artículo científico publicado en 2008
The prognostic significance of serum beta2 microglobulin levels in acute myeloid leukemia and prognostic scores predicting survival: analysis of 1,180 patients
artículo científico publicado en 2008
The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate
artículo científico publicado en 2003
The role of JAK pathway dysregulation in the pathogenesis and treatment of acute myeloid leukemia
artículo científico publicado en 2012
The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors
artículo científico publicado en 2006
The role of clofarabine in acute myeloid leukemia
artículo científico publicado en 2012
The role of clofarabine in hematologic and solid malignancies--development of a next-generation nucleoside analog
artículo científico publicado en 2005
The role of craniospinal irradiation in adults with a central nervous system recurrence of leukemia
artículo científico publicado en 2004
The role of cytogenetic abnormalities as a prognostic marker in primary myelofibrosis: applicability at the time of diagnosis and later during disease course
artículo científico publicado en 2009
The role of decitabine in the treatment of myelodysplastic syndromes
artículo científico publicado en 2007
The role of gemtuzumab ozogamicin in acute leukaemia therapy
artículo científico publicado en 2006
The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma
artículo científico publicado en 2002
The role of ponatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia
artículo científico
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
artículo científico publicado en 2004
The synthetic heat shock protein 90 (Hsp90) inhibitor EC141 induces degradation of Bcr-Abl p190 protein and apoptosis of Ph-positive acute lymphoblastic leukemia cells
artículo científico publicado en 2010
The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia
artículo científico publicado en 2004
The use of nilotinib or dasatinib after failure to 2 prior tyrosine kinase inhibitors: long-term follow-up
scientific article published on 03 September 2009
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years
artículo científico publicado en 2008
Therapeutic benefit of decitabine, a hypomethylating agent, in patients with high-risk primary myelofibrosis and myeloproliferative neoplasm in accelerated or blastic/acute myeloid leukemia phase
artículo científico publicado en 2015
Therapeutic effects of ruxolitinib in patients with myelofibrosis without clinically significant splenomegaly
artículo científico publicado en 2012
Therapy of core binding factor acute myeloid leukemia: incremental improvements toward better long-term results
artículo científico publicado en 2012
Therapy with the histone deacetylase inhibitor pracinostat for patients with myelofibrosis
artículo científico publicado en 2012
Therapy-related acute myelogenous leukemia and myelodysplastic syndrome in patients with acute lymphoblastic leukemia treated with the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimens
artículo científico publicado en 2009
Therapy-related myelofibrosis does not appear to exist
scientific article published on 26 May 2017
Third-generation tyrosine kinase inhibitors and beyond
scientific article published on October 2010
Thrombocytopenia in patients with myelodysplastic syndromes
artículo científico publicado en 2010
Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients
artículo científico publicado en 2008
Time to abandon traditional chemotherapy for acute promyelocytic leukaemia?
artículo científico publicado en 2015
Time to blur the blast boundaries
scientific article published in 2022
Time to response and survival in hypomethylating agent-treated acute myeloid leukemia
artículo científico publicado en 2017
Time-dependent changes in mortality and transformation risk in MDS.
artículo científico publicado en 2016
Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients
scientific article published on 14 July 2020
Toward Individualized Therapy in Acute Myeloid Leukemia: A Contemporary Review
artículo científico
Toward the potential cure of leukemias in the next decade
scientific article published on 06 October 2018
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
artículo científico publicado en 2003
Translocation t(1;19)(q23;p13) in adult acute lymphoblastic leukemia - a distinct subtype with favorable prognosis
scientific article published on 21 September 2020
Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study
artículo científico publicado en 2019
Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis
artículo científico publicado en 2017
Treatment of FLT3-ITD-positive acute myeloid leukemia relapsing after allogeneic stem cell transplantation with sorafenib
artículo científico publicado en 2011
Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate
artículo científico publicado en 2003
Treatment of Philadelphia chromosome-positive chronic myelogenous leukemia with weekly polyethylene glycol formulation of interferon-alpha-2b and low-dose cytosine arabinoside
artículo científico publicado en 2003
Treatment of acute lymphoblastic leukemia in older adults: now and the future
artículo científico
Treatment of adult acute lymphoblastic leukemia (ALL) with a focus on emerging investigational and targeted therapies
artículo científico publicado en 2012
Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin
artículo científico publicado en 2017
Treatment of chronic myelogenous leukemia as a paradigm for solid tumors: how targeted agents in newly diagnosed disease transformed outcomes
artículo científico publicado en 2012
Treatment of core-binding-factor in acute myelogenous leukemia with fludarabine, cytarabine, and granulocyte colony-stimulating factor results in improved event-free survival
artículo científico publicado en 2008
Treatment of febrile neutropenic patients with cancer who require hospitalization: a prospective randomized study comparing imipenem and cefepime
artículo científico publicado en 2003
Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options
artículo científico publicado en 2012
Treatment of philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate.
artículo científico publicado en 2002
Treatment options for chronic myeloid leukemia
artículo científico
Treatment selection after imatinib resistance in chronic myeloid leukemia
artículo científico publicado en 2009
Treatment with FLT3 inhibitor in patients with FLT3-mutated acute myeloid leukemia is associated with development of secondary FLT3-tyrosine kinase domain mutations
artículo científico publicado en 2014
Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia
artículo científico publicado en 2015
Treatment with PF-04449913, an oral smoothened antagonist, in patients with myeloid malignancies: a phase 1 safety and pharmacokinetics study.
artículo científico publicado en 2015
Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial
scientific article published on 10 December 2018
Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009.
artículo científico publicado en 2012
Trends in the management of chronic myelogenous leukemia
artículo científico publicado en 2005
Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells
artículo científico publicado en 2009
Troxacitabine activity in extramedullary myeloid leukemia
artículo científico publicado en 2002
Troxacitabine and imatinib mesylate combination therapy of chronic myeloid leukaemia: preclinical evaluation
artículo científico publicado en 2004
Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia
artículo científico publicado en 2012
Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study
artículo científico publicado en 2013
Tyrosine kinase inhibition: a therapeutic target for the management of chronic-phase chronic myeloid leukemia
artículo científico publicado en 2013
Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
scholarly article by Kamal Chamoun et al published 3 January 2019 in Journal of Hematology & Oncology
Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukemia
artículo científico publicado en 2009
Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase
artículo científico publicado en 2013
Tyrosine kinase inhibitors for chronic myelogenous leukemia.
artículo científico publicado en 2007
Tyrosine kinase inhibitors in acute and chronic leukemias
artículo científico
Ubiquitin–proteasome system profiling in acute leukemias and its clinical relevance
⬇️
artículo científico publicado el 15 de octubre de 2010
Unraveling Myelodysplastic Syndromes: Current Knowledge and Future Directions
artículo científico
Unrecognized fluid overload during induction therapy increases morbidity in patients with acute promyelocytic leukemia
scientific article published on 31 May 2019
Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome
artículo científico publicado en 2007
Update: chronic myelogenous leukemia clinical practice guidelines.
artículo científico publicado en 2003
Ursodiol does not prevent hepatic venoocclusive disease associated with Mylotarg therapy
artículo científico publicado en 2002
Use of all-trans retinoic acid plus arsenic trioxide as an alternative to chemotherapy in untreated acute promyelocytic leukemia
artículo científico publicado en 2005
Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience
artículo científico publicado en 2003
Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm
artículo científico
Valganciclovir prevents cytomegalovirus reactivation in patients receiving alemtuzumab-based therapy
artículo científico publicado en 2007
Validation of a clinical assay of multi-locus DNA methylation for prognosis of newly diagnosed AML.
artículo científico publicado en 2017
Validation of a post-hypomethylating agent failure prognostic model in myelodysplastic syndromes patients treated in a randomized controlled phase III trial of rigosertib vs. best supportive care
artículo científico publicado en 2017
Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes
artículo científico publicado en 2012
Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3-internal tandem duplication genotypes
scientific article published on 06 December 2018
Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories
artículo científico publicado en 2018
Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse
scientific article published on 01 July 2006
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
scholarly article by Courtney D DiNardo et al published 25 October 2018 in Blood
Venetoclax with Decitabine Versus Intensive Chemotherapy in Acute Myeloid Leukemia: A Propensity Score Matched Analysis Stratified by Risk of Treatment-related Mortality
scientific article published on 02 December 2020
Very high levels of lactate dehydrogenase at diagnosis predict central nervous system relapse in acute promyelocytic leukaemia
artículo científico publicado en 2014
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapy
artículo científico publicado en 2012
Vosaroxin in combination with decitabine in newly diagnosed older patients with acute myeloid leukemia or high-risk myelodysplastic syndrome
artículo científico publicado en 2017
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study
artículo científico publicado en 2015
WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells
artículo científico publicado en 2007
WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation
artículo científico publicado en 2008
Which tyrosine kinase inhibitor should we use to treat Philadelphia chromosome-positive acute lymphoblastic leukemia?
artículo científico publicado en 2017
Whole-arm translocation of der(5;17)(p10;q10) with concurrent TP53 mutations in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): A unique molecular-cytogenetic subgroup.
artículo científico publicado en 2016
Why are cancer drugs so expensive in the United States, and what are the solutions?
artículo científico
XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38− cells in a phase 1/2 study of patients with relapsed/refractory AML
⬇️
artículo científico publicado el 1 de enero de 2011
Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases
artículo científico publicado en 2005
inv(16)(p13q22) in chronic myelogenous leukemia in blast phase: a clinicopathologic, cytogenetic, and molecular study of five cases.
artículo científico publicado en 2005
mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy
t(3;21)(q26;q22) in myeloid leukemia: an aggressive syndrome of blast transformation associated with hydroxyurea or antimetabolite therapy
artículo científico publicado en 2006